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ABSTRACT  
   
 
Malignant brain tumors are devastating despite aggressive treatments such as 
surgical resection, chemotherapy and radiation therapy. The average life expectancy of 
patients with newly diagnosed glioblastoma is approximately 15 months. One novel 
therapeutic strategy involves using a ketogenic diet (KD) which increases circulating 
ketones and reduces circulating glucose. While the preclinical work has shown that the 
KD increases survival, enhances radiation and alters several pathways in malignant 
gliomas, its impact on the anti-tumor immune response has yet to be examined. This 
dissertation demonstrates that mice fed the KD had increased tumor-reactive innate and 
adaptive immune responses, including increased cytokine production and cytolysis via 
tumor-reactive CD8+ T cells. Additionally, we saw that mice maintained on the KD had 
increased CD4 infiltration, while T regulatory cell numbers stayed consistent. Lastly, 
mice fed the KD had a significant reduction in immune inhibitory receptor expression as 
well as decreased inhibitory ligand expression on glioma cells, namely programmed 
death receptor -1 (PD-1) and its ligand programmed death receptor ligand -1 (PD-L1). 
Further, it is demonstrated that the ketone body beta-hydroxybutyrate (BHB) reduces 
expression of PD-L1 on glioma cells in vitro suggesting it may be responsible in part for 
immune-related changes elicited by the KD. Finally this dissertation also shows that the 
KD increases the expression of microRNAs predicted to target PD-L1 suggesting a 
potential mechanism to explain the ability of the KD to modulate immune inhibitory 
checkpoint pathways. Taken together these studies shed important light on the 
mechanisms underlying the KD and provide additional support for its use an adjuvant 
therapy for malignant glioma.  
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CHAPTER 1 
 
INTRODUCTION 
 
Human malignant glioma is a uniformly fatal disease due, in part, to the 
limitations of currently available treatments which include surgery, chemotherapy and 
radiation therapy. Average survival of patients with glioblastoma multiforme (GBM) is 1.5 
years, and tumors of the central nervous system are the most common solid tumor in the 
pediatric population. It is therefore of paramount importance that new therapeutic 
strategies for brain cancer patients be developed, especially those that can enhance the 
efficacy of current treatment options without damaging normal brain tissue. Advances in 
our understanding of the biology of these tumors has led to an increase in the number of 
targeted therapies in preclinical and clinical trials [1]. While these therapies may prove 
somewhat effective, the heterogeneity of this tumor often precludes the targeted 
molecules from being found on all cells in the tumor thus reducing the efficacy of these 
treatments. In contrast, one trait shared by virtually all tumor cells is altered metabolism. 
 
Tumor Metabolism 
 
Alterations in the metabolism of cancer cells, what we now call the “Warburg 
effect” or aerobic glycolysis, was first described by Otto Warburg in 1927 [2]. Cancer 
cells use glycolysis to provide energy and biomolecules regardless of the availability of 
oxygen. This results in the production of fewer ATP molecules per molecule of glucose, 
and thus tumor cells require large amounts of glucose. This shift towards increased 
glycolytic flux in the cytosol and away from the tricarboxylic acid cycle and oxidative 
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phosphorylation in the mitochondria occurs very early in tumorigenesis. This allows for 
rapid cell proliferation even under conditions of hypoxia and in the presence of 
dysfunctional mitochondria. Since Warburg’s discovery, metabolism has been of interest 
in the cancer field but it often seemed overshadowed by discoveries of oncogenes, 
tumor suppressor genes, growth factor pathways, molecular subtypes of cancers, etc. 
There is a resurgence of interest in metabolism as a central theme in cancer, and we 
continue to find that metabolic pathways intersect and often regulate key components of 
tumor initiation, progression and therapy response [3, 4]. In fact, altered metabolism 
itself has been referred to as a hallmark of cancer [5, 6] in addition to being involved in 
virtually all of the cancer hallmarks described in the seminal paper by Hanahan and 
Weinberg [7] (Figure 1, [8]). 
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Figure 1: An illustration of the interconnections between tumor metabolism with 
Hanahan and Weinberg’s Hallmarks of Cancer [8].  
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The term “metabolic remodeling” has been used to describe metabolic changes 
that can occur in cancer cells [9], and oncogene associated pathways are now known to 
intersect with, and alter metabolic pathways. For example, the tumor suppressor protein 
p53 which plays a pivotal role in the cellular responses to hypoxia, DNA damage and 
oncogene activation is now known to regulate glycolysis and assist in maintaining 
mitochondrial integrity [9]. Another important connection between metabolism and tumor 
growth is through regulation of c-MYC. Over-expression of c-MYC occurs in a wide 
variety of cancers including gliomas. C-MYC is a multi-functional transcription factor and 
the list of its target genes include those involved in both cell proliferation and cell 
metabolism [10]. In addition to stimulating glycolysis, c-MYC has been found to activate 
glutaminolysis and lipid synthesis from citrate [9].  
With the advent of molecular analyses, studies of growth factor pathways 
seemed to overshadow the influence of metabolism on cancer growth. Over-activation of 
the stress responsive PI3K/AKT signaling pathway is typical in many cancers and often 
due to activation of growth factor signaling pathways involved in glioma growth such as 
platelet-derived growth factor, epidermal growth factor and insulin growth factor.  We 
now know that these growth factor pathways are intertwined with metabolic signally 
pathways [11-14]. PI3K/AKT signaling has been closely linked to metabolism and under 
low glucose conditions results in rapid tumor cell death [15]. 
Another important “hub” linking metabolism and cancer is hypoxia-inducible 
factor 1 (HIF-1). HIF-1 expression is activated by hypoxia, which is typically found in high 
grade gliomas and other cancers. HIF-1 is a heterodimeric transcription factor that 
induces the transcription of a variety of genes involved in angiogenesis (vascular 
endothelial growth factor (VEGF) and other cytokines) in an attempt to improve tissue 
perfusion. This results in the formation of abnormal blood vessels that can increase 
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inflammation and edema in brain tumors, as well as induction of the transcription of a 
variety of genes that promote invasion, migration and tumor growth [16, 17]. In addition 
to specific actions that relate to the tumor cell’s response to oxygen availability, HIF-1 
interacts with the PI3K/AKT signaling path to act as a regulator of cancer metabolism, 
proliferation and glycolysis [12, 17-19]. HIF-1 may, at least in part, provide the molecular 
basis for the Warburg effect by “reprograming” cellular metabolism in response to 
oxygen availability [12, 20]. HIF-1 also is a central figure in alterations to the tumor 
microenvironment which not only affects tumor cell growth, but also response to therapy 
[15, 17, 21]. It also affects the activation of nuclear factor – kappa B (NF-κB), a 
transcriptional activator that is central to the regulation of various signal transduction 
pathways and to transcriptional activation events that mediate inflammation, cell 
proliferation, cell migration, and angiogenesis. 
The molecular background of a tumor cell can also affect the regulation of the 
pathways described above. Loss of function of phosphatase and tensin homolog (PTEN) 
or mutation of p53 also increase HIF-1, as does the accumulation of reactive oxygen 
species (ROS). ROS are multi-faceted effector molecules involved in numerous cellular 
pathways, including those regulating autophagic/apoptotic responses to genotoxic 
stress, hypoxia and nutrient deprivation. Cancer cells often have increased levels of 
ROS [22] and they have been implicated in angiogenesis induction and tumor growth 
through the regulation of VEGF and HIF-1 [23].  
It is clear that cancer cell metabolism is far more complex than originally thought.  
A number of cancer associated mutations affect metabolism and defects in mitochondria 
are seen in cancer that also link metabolism with cancer initiation and progression.  
Although some of these interactions are mentioned above, in-depth discussions of all of 
the interactions that occur between cancer and metabolism are beyond the scope of this 
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dissertation and the reader is referred to a number of reviews on these subjects [5, 6, 
22, 24, 25]. The fact that metabolic dysregulation is seen in virtually all tumor cells has 
led to suggestions that a promising therapeutic strategy may be to exploit this feature. 
One potential way to achieve this goal is through the use of the therapeutic ketogenic 
diet (KD) or physiologically similar methods, such as caloric restriction or intermittent 
fasting.  
 
The Ketogenic Diet 
 
The ketogenic diet (KD) is more correctly referred to as “metabolic therapy” 
rather than a “diet”. This high-fat low protein/carbohydrate diet is used to treat refractory 
epilepsy in children, and more recently in some adults [26, 27]. The diet is not without 
side effects; however, these are typically readily managed when the patient has 
appropriate supervision by a registered dietitian skilled in its use. The KD has been 
shown to have neuroprotective effects and there are now studies to determine its 
efficacy for the treatment of a number of neurological disorders, including Alzheimer’s 
disease, traumatic brain injury, amyotrophic lateral sclerosis and autism [28-30]. The KD 
increases blood ketones and decreases blood glucose by simulating the physiological 
response to fasting, thus leading to high rates of fatty acid oxidation and an increase in 
the production of acetyl coenzyme A (acetyl-CoA). When the amount of acetyl-CoA 
exceeds the capacity of the tricarboxylic acid cycle to utilize it, there is an increase in the 
production of the ketone bodies β-hydroxybutyrate (BHB) and acetoacetate (ACA), 
which can be used as an energy source in the normal brain [31-35]. Since normal cells 
readily use ketones as an alternate energy source, they are unlikely to be adversely 
affected by reduced glucose. In contrast, the metabolic alterations found in cancer cells 
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are generally thought to reduce their ability to be “flexible” regarding their primary energy 
source, and thus they require glucose [36-42]. This lends credence to the theory that 
reduction in glucose that results from the ketogenic diet essentially “starves” the tumor 
cells and inhibits their growth [43-49]. Thus when used as a therapy, the KD may take 
advantage of the Warburg effect.  
In addition to the effects mediated by glucose reduction, more recent work in 
cancer research has shown that the ketogenic diet can exhibit anti-tumor effects even in 
the absence of glucose reduction. We demonstrated the effect of adding ketones to 
media containing glucose in vitro using the AO2V4 cell line [50]. This cell line was 
derived from a recurrent human glioblastoma and is grown in Waymouth’s MAB 87/3 
media containing 28mM glucose and supplemented with 20% fetal calf serum. When 
5mM BHB plus 5mM ACA was added to complete media, cell growth was significantly 
inhibited. When 1,3-bis(2-chloroethyl)-1 nitrosourea (BCNU, carmustine), one of the 
chemotherapeutic agents given to this patient prior to tumor recurrence was used in 
addition to ketones there was additional growth inhibition compared to either ketones or 
BCNU alone. Additional work has shown that the ketones themselves exert antitumor 
effects separate from the effects of reduced blood glucose [50-52]. The ketone BHB has 
recently been shown to inhibit histone deacetylases (HDACs) which can result in 
epigenetic suppression of the expression of a variety of genes.  Thus, ketones may 
provide a link between metabolism and tumorigenesis, although the precise nature of 
these changes is as yet unknown [53-56]. The concept of ketone treatment in the 
absence of glucose reduction will be explored further in Chapter 3 of this dissertation.   
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Preclinical Evidence 
 
The use of metabolic alteration for the therapy of brain tumors has been 
championed by Seyfried and colleagues. They used the VM [57] and CT-2A [58] mouse 
tumor models to show that a ketogenic diet (KD), especially when given in restricted 
amounts, extends survival. D’Agostino and colleagues have added hyperbaric oxygen 
and exogenous ketone supplementation to demonstrate reduced tumor cell growth and 
metastatic spread in the VM metastatic tumor model [59, 60]. We used the syngeneic 
intracranial GL261-luc/albino C57/Bl6 model to demonstrate that caloric restriction was 
not necessary for the anti-tumor effect of the KD [61], particularly when a 4:1 
fat:carbohydrate plus protein formulation is used [50].  
The KD and similar diets used as a monotherapy have a pluripotent effect on the 
growth of tumors both in vitro and in vivo which may depend, at least in part, on the 
model system, the specific metabolic intervention and the molecular underpinnings of 
the tumor itself [48, 60-70]. The striking feature of the work done to date is that 
alterations in metabolism have a far reaching effect on tumor cells, tumors and the tumor 
microenvironment. Studies have shown reductions in growth rate as one might expect; 
however, there are also changes in the formation of reactive oxygen species and 
oxidative stress [71-73], angiogenesis [38, 43, 62, 74], hypoxia [37, 60, 62], inflammation 
and peri-tumoral edema [62, 64, 75], metastasis and invasion [60, 65, 68, 70, 76, 77] 
and the expression of various transcriptional modulators such as NF-κB [62] and c-MYC 
(unpublished data, Scheck et al.).  
 
 
 
  9 
KD in Combination with Standard Therapies 
 
Although evidence suggests that the KD provides anti-tumor benefits on its own, 
perhaps the most effective use of the KD is in combination with standard cancer 
therapies such as radiation and chemotherapy [78]. The KD greatly enhanced survival in 
a mouse model of malignant glioma when combined with TMZ when compared to either 
treatment alone (Figure 2) [79]. Using a bioluminescent, syngeneic intracranial model of 
malignant glioma, the KD was also shown to significantly potentiate the anti-tumor effect 
of radiotherapy. In fact, 9 out of 11 animals maintained on the KD and treated with 
radiation had complete and sustained remission of their implanted tumors, even after 
being switched back to a standard rodent diet (Figure 2) [80]. Allen et al reported similar 
results when the KD is combined with radiation and chemotherapy in a lung cancer 
xenograft model [72]. That is, they found decreased tumor growth rate and increased 
survival. CR and short-term fasting have also been found to be synergistic with radiation 
and other anti-cancer therapeutics in both preclinical and clinical studies [42, 63, 81-89]. 
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Figure 2: The KD enhances survival of glioma bearing mice. Kaplan-Meier survival 
plot of animals implanted intracranially with GL261-luc2 malignant glioma cells and (A) 
maintained on KetoCal [KC, a 4:1 fat:carbohydrate plus protein formulation of the 
ketogenic diet (KD)] vs. standard diet (SD); (B) treated with 2x4Gy radiation vs.KC plus 
radiation, and (C) treated with 50 mg/kg temozolomide (TMZ) vs. KC plus TMZ. Animals 
on KC survived significantly longer when treated with KC alone, when KC was combined 
with radiation, and when KC was combined with TMZ. [50, 80].  
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The effectiveness of radiation therapy is due to a number of factors including 
relative damage done to tumor cells versus normal tissue and the ability of normal cells 
and tumor cells to repair the damage [81]. Radiation works, in part, by creating ROS 
through the radiolysis of water. The ROS damage the DNA and other macromolecules, 
causing sub-lethal damage that can become lethal if not repaired. The potentiation of 
radiation therapy by the KD or caloric restriction seems paradoxical in light of our data 
demonstrating a reduction in ROS in tumors from animals maintained on a KD [61]. 
However, radiation effects do not only occur through ROS, and radiation can directly 
damage DNA and other cellular macromolecules. Furthermore, in addition to reactive 
oxygen species, radiation causes the production of reactive nitrogen species (RNS), a 
potential source of macromolecular damage following radiation [90]. Whether the KD 
and/or caloric restriction reduces the formation of RNS is as yet unknown. In fact, the 
main effect of the KD or CR may not be in altering the amount of radiation-induced 
damage, but may in fact be in modulating the ability of tumor and normal cells to repair 
radiation-induced damage [91]. Studies have shown that caloric restriction can enhance 
DNA repair in normal cells [92]; however, this may not be the case in tumor cells, and 
the differential response of tumor cells and normal cells to genotoxic stress may be 
mediated by reduced IGF-1 and glucose in the tumor cells. We and others have shown 
that insulin growth factor is reduced in animals maintained on a ketogenic diet [50, 64, 
67, 81]. In addition, a number of studies have shown that reduced activation of the 
PI3K/Akt pathway, activation of the adenosine monophosphate-activated protein kinase 
(AMPK) signaling pathway, and reduction of receptor tyrosine kinase growth factor 
pathways can all reduce radioresistance in tumor cells [93-101].  
The variety of effects seen when glucose in lowered and/or ketones are 
increased suggests that this may also potentiate other therapies, including newer 
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immune- and targeted therapies. Concerns that potentiation of the anti-tumor effect of a 
particular therapy may also increase its effect on normal brain are valid; however, we 
and others have shown that the gene expression changes seen in tumor are different 
than those seen in normal brain [37, 61, 102]. Further, the KD is known to have 
neuroprotective effects [29, 74, 103, 104] and thus it has been postulated that this may 
actually help to protect the normal brain from the deleterious effects of radio and 
chemotherapy. Taken together, the preclinical data provides strong support for the 
clinical use of the KD or caloric restriction as an adjuvant therapy for the treatment of 
gliomas and other cancers.  
Chapter 3 of this dissertation will further explore the mechanisms and specifically 
the role of BHB in the radiation-enhancing properties of the KD. 
 
KD In Human Cancer Patients 
 
Studies of glucose utilization in cancer go back prior to the 1980s, including 
studies of metabolism and cancer cachexia [40, 105]. These and other studies 
suggested that the ketogenic diet consisting of a high percentage of medium chain 
triglycerides (MCT) along with various supplements resulted in weight gain and improved 
nitrogen balance in both animals and humans. In 1995 Nebeling and colleagues 
published a case report in which they used a similar ketogenic diet based on MCT oil to 
treat 2 female pediatric patients with advanced stage malignant brain tumors [106, 107]. 
They demonstrated that dietary induced ketosis decreased the availability of glucose to 
the tumor without causing a decrease in patient weight or overall nutritional status. 
Furthermore, both children had long-term tumor management [107]. The 2nd case report 
was published in 2010 by Zuccoli and coworkers [108]. This patient was a 65-year-old 
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female with a multicentric glioblastoma. She was put on a 4:1 (ratio of fats:carbohydrate 
plus protein) calorie restricted (600kcal/day) ketogenic diet during radiation and 
chemotherapy. During this time her body weight dropped by 20%, she had reduced 
blood glucose, increased urinary ketones and, most importantly, no observable brain 
tumor by either fluorodeoxyglucose Positron Emission Tomography (FDG-PET) or 
magnetic resonance imaging (MRI). The tumor recurred ten weeks after the patient 
resumed her normal eating habits and she succumbed to her disease less than 2 years 
after diagnosis. While this patient did not experience long-term tumor control after 
cessation of the diet, this report demonstrated that the diet could be tolerated, even 
when used in a calorie-restricted setting. Results of a phase 1 clinical trial were reported 
in 2011 by a German group [109]. Tolerability of a restricted calorie ketogenic diet was 
tested in 16 patients with a variety of advanced (end-stage) cancers. There were no 
severe side effects and 5 of the 16 patients were able to complete the 3 month 
treatment. These 5 patients had stable disease while on the diet. Two of the 11 
remaining patients died early following the beginning of the trial, one was unable to 
tolerate the diet and dropped out immediately, 2 patients dropped out for personal 
reasons, one was unable to continue the diet for more than a month and 3 had disease 
progression within less than 2 months of starting the diet and one dropped out to resume 
chemotherapy. While this trial demonstrated tolerability and favorable side effect profile, 
the antitumor efficacy could not be assessed due to the variety and severity of disease in 
the patients. Recently, Schwartz et al reported on 2 patients with recurrent GBM treated 
with a calorie restricted ketogenic diet as a monotherapy and although the diet was 
tolerated, both patients showed tumor progression - the first within 4 weeks and the 
second within 12 weeks of beginning the protocol [110]. More recently, a number of 
prospective clinical trials have been initiated which have been summarized in Table 1. 
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These trials include studies of up-front treatment using the KD in addition to standard 
radiation and chemotherapy in patients diagnosed with GBM. 
  15 
 
Table 1: Active clinical trials exploring ketogenic diets in malignant glioma patients. 
  
ClinicalTrials.gov 
Identifier
Title Phase Location
NCT01865162
Ketogenic Diet as Adjunctive Treatment in 
Refractory/Endstage Glioblastoma Multiforme: 
a Pilot Study (KGDinGBM)
I 
MidAtlantic Epilepsy and 
Sleep Center, Bathesda, 
Maryland, US
NCT03451799
Ketogenic Diet in Combination With Standard-
of-care Radiation and Temozolomide for 
Patients With Glioblastoma
I
Cedars Sinai Medical 
Center, Los Angeles, 
California, United States
NCT01535911
Pilot Study of a Metabolic Nutritional Therapy 
for the Management of Primary Brain Tumors
I
Michigan State 
University/Sparrow 
Hospital, East Lansing, 
Michigan, United States
NCT02302235
Ketogenic Diet Treatment Adjunctive to 
Radiation and Chemotherapy 
in Glioblastoma Multiforme: a Pilot Study 
(GBMXRT)
II
MidAtlantic Epilepsy and 
Sleep Center, Bathesda, 
Maryland, US
NCT02286167
Glioma Modified Atkins-based Diet in Patients 
With Glioblastoma (GLAD)
I
The Johns Hopkins 
Hospital, Baltimore, 
Maryland, US
NCT03278249
Feasibility Study of Modified Atkins Ketogenic 
Diet in the Treatment of Newly Diagnosed 
Malignant Glioma
I
UC Health, Cincinnati, 
Ohio, United States
NCT02939378
Ketogenic Diet Adjunctive to Salvage 
Chemotherapy for Recurrent Glioblastoma: A 
Pilot Study
I/II
Beijing Tiantan Hospital, 
Bejing, Beijing, China
NCT00575146 Ketogenic Diet for Recurrent Glioblastoma I
Senckenberg Institute of 
Neurooncology, 
Frankfurt, Germany 
NCT03160599
Restricted Calorie Ketogenic Diet as a 
Treatment in Glioblastoma Multiforme
I
Guangzhou Medical 
University, Guangzhou, 
Guangdong, China
NCT01754350
Calorie-restricted, Ketogenic Diet and 
Transient Fasting During Reirradiation for 
Patients With Recurrent Glioblastoma
I 
Senckenberg Institute of 
Neurooncology, 
Frankfurt, Germany 
NCT03075514
Ketogenic Diets as an Adjuvant Therapy 
in Glioblastoma (KEATING)
I
University of Liverpool, 
Liverpool, Merseyside, 
United Kingdom
Active Clinical Trials: Ketogenic Diet and Gliomas
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The case reports described above along with numerous anecdotal reports 
suggest that the KD may be a promising anti-cancer therapy; however, more work is 
needed to determine how to best utilize this, and other metabolic therapies for the 
treatment of tumors. Most of the information regarding the use of the ketogenic diet 
comes from the epilepsy literature. Further research is needed to determine optimum 
blood ketone and glucose levels for anticancer effects. In addition, a variety of ketogenic 
diets are used for seizure control and it is not clear if one or more of the different 
formulations will provide the best results for cancer patients [111]. Finally, while the KD 
has a long record of safety in the epilepsy community, side effects that occur when used 
in combination with cancer therapies may differ in type or severity. This data will come 
from carefully controlled clinical trials that include input from registered dietitians well-
versed in the use of the KD. Patient enrollment into clinical trials requires “buy-in” from 
the medical community. Physicians must be educated on the therapeutic benefits of 
metabolic alteration as an adjuvant therapy. As with any decision regarding therapy, the 
patient’s overall condition, including nutritional status, must be taken into account. As 
suggested by Klement and Champ [81], cancer patients should be assessed for 
nutritional needs and tolerability of such interventions. 
Concern about patients’ quality of life is sometimes given as a reason not to 
employ KD. Compliance can be made more difficult by the use of steroids (prescribed for 
peritumoral edema) that often increase hunger and raise blood glucose levels. To 
address this, at least one clinical trial (NCT02046187) includes an analysis of both 
patient and caregiver quality of life. Quality of life measurements are being added to 
more clinical trials, as the importance of this has become recognized at the national level 
[112-114]. While some clinicians are concerned compliance will reduce quality of life, the 
patients that do remain on the KD often comment that this allows them to participate in 
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their own therapy. Despite these caveats, the existing preclinical data suggesting anti-
tumor efficacy and a synergistic effect with standard therapies provides a strong impetus 
to conduct controlled clinical trials, particularly those that will shed light on the 
interactions between the KD and other therapies. 
 
Introduction to Immunosuppression and the PD-1/PD-L1 pathway in GBM  
 
 Evasion of the immune system has emerged as a crucial hallmark of GBM. 
These tumors exert a variety of immunosuppressive pressures on the surrounding 
microenvironment including increased induction of T regulatory cells (Tregs), elevated 
immunosuppressive cytokine levels, diminished CD4+ helper T cell populations, 
tolerized antigen presenting cells and upregulated immune inhibitory checkpoints [115]. 
There are multiple immunotherapeutic approaches for cancer in development [116, 117]; 
however, the success of therapies targeting immune inhibitory checkpoint pathways in 
other cancers, particularly those inhibiting the PD-1/PD-L1 axis, have generated 
increased interest in their use for GBM. Programmed cell death-1 (PD-1) is a receptor 
found on the surface of activated effector T cells and acts as a checkpoint to regulate 
immune proliferation and activation. When PD-1 binds its ligand, programmed death 
ligand 1 (PD-L1), CD8+ and CD4+ T cell activation is suppressed [118]. Tumor-
infiltrating lymphocytes can express high levels of PD-1 which may reflect an exhausted 
phenotype and poor effector function [119]. Increased PD-L1 expression has been 
observed on tumor cells and immune cells within the GBM microenvironment [119-122] 
and leads to direct inactivation of CD8+ T cells [123, 124] (Figure 3). Further, many 
studies have demonstrated that high expression of PD-L1 in tumor tissues is correlated 
with glioma grade [125]. 
  18 
Figure 3: PD-L1 immune inhibitory checkpoint mechanism. Tumor cells can express 
the inhibitory ligand PD-L1 which binds to the receptor PD-1 on T cells. This lead to 
decreased activation and effector capabilities of the T cell in the tumor microenvironment 
[126].  
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The main focus of our work is to understand and develop the ketogenic diet as 
an adjuvant to standard therapies and newer emerging therapeutic strategies for brain 
tumors. We therefore sought to explore the impact of the KD on the anti-glioma immune 
response and in particular the immune inhibitory checkpoint pathways. We previously 
published a study demonstrating that the KD alters pathways involved in hypoxia, 
angiogenesis, invasive potential in a mouse model of malignant glioma [62]. This 
suggested that the KD may alter the way a tumor shapes and interacts with its 
microenvironment, leading us to hypothesize that it may also impact specific 
components of the immune system. These earlier studies taken together with the 
growing interest in implementing immunotherapeutic strategies for GBM provided the 
initial impetus for conceiving the studies described in this dissertation.   
 
Chapter Organization 
 
Chapter 2 of this dissertation, titled  Enhanced Immunity in a Mouse Model of 
Malignant Glioma is Mediated by a Therapeutic Ketogenic Diet, will discuss the evidence 
demonstrating that a ketogenic diet works as an immune adjuvant in vivo. This work has 
been published [127] and use in this document is permitted under the Creative 
Commons Attribution 4.0 International License. This study was completed in 
collaboration with Danielle Lussier, PhD, who co-authored the publication. This chapter 
includes the manuscript in its entirety. 
Chapter 4 of this dissertation The Ketone Body Beta Hydroxybutyrate Reduces 
Expression of PD-L1 on Glioma Cells but Does Not Impact Expression of PD-1 on T 
cells In Vitro, will discuss the evidence exploring the ability of the ketone body BHB to 
recapitulate the effects of the full KD. Namely, this chapter focuses on the impact of BHB 
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on PD-L1 expression in glioma cells and PD-1 expression on T cells. Potential 
mechanisms regulating PD-L1 expression including constitutive oncogenic signaling and 
adaptive expression will be discussed. This work has not yet been published.  
Chapter 5 of this dissertation titled, The Ketogenic Diet Increases the Expression 
of MicroRNAs  Predicted to Target PD-L1, will discuss data demonstrating that the KD 
increases the expression of several different microRNAS. These microRNAs target 
multiple pathways in glioma biology including immune inhibitory checkpoint pathways. 
This work has not yet been published.  
Chapter 6 of this dissertation, titled Discussion, will discuss the broader 
implication of the previous three chapters in improving our understanding of ketogenic 
diets for the adjuvant treatment of malignant glioma. 
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CHAPTER 2 
 
ENHANCED IMMUNITY IN A MOUSE MODEL OF MALIGNANT GLIOMA IS 
MEDIATED BY A THERAPEUTIC KETOGENIC DIET 
 
INTRODUCTION 
 
Glioblastoma multiforme (GBM) is a highly aggressive, heterogeneous brain 
tumor with poor prognosis [128]. Standard of care includes surgical resection followed by 
radiation and chemotherapy, however median survival is about 15 months with a two-
year survival of 30% and a 5-year survival of <5% in adults [129]. Despite breakthroughs 
in our understanding of the disease, therapeutic options available for GBM have 
remained largely unchanged over the past three decades. This has led to only marginal 
increases in overall patient survival and new therapeutic approaches to enhance brain 
tumor treatment are warranted.  
One novel therapeutic approach for GBM involves targeting a phenotypic trait 
shared by virtually all cancer cells, deregulated metabolism. It has been postulated that 
metabolic alteration such as that seen with the therapeutic ketogenic diet (KD) may be 
an effective anti-cancer strategy [79]. The KD is a high fat, low-carbohydrate/adequate 
protein nutritional therapy used in the treatment of refractory epilepsy [28]. We and 
others have shown that the KD enhances survival in mouse models of malignant glioma 
[38, 43, 61, 80]. We also demonstrated that the KD greatly enhanced survival when 
administered in combination with radiation [80]. Mechanistically, the KD alters a variety 
of processes that influence the tumor microenvironment including hypoxia, inflammation, 
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angiogenesis and vascular permeability [61, 62]. However, the effect of a KD on the 
GBM tumor-reactive immune response has yet to be examined.  
We have recently shown that an unrestricted KD decreases expression of the 
hypoxia marker carbonic anhydrase IX (CAIX) and the key mediator of the hypoxic 
response hypoxia-inducible factor alpha (HIF-1α) in a mouse model of malignant glioma 
[62]. Wei et al. demonstrated that hypoxia leads to inhibition of T cell proliferation and 
effector responses, with induction of CD4+FoxP3+ T regulatory cells in GBM [130]. This 
study also demonstrated that this immunosuppressive effect could be reversed by 
inhibiting HIF-1α. As tumor hypoxia is linked to the less favorable Th2 immune response 
[131], it is possible that by altering the hypoxic response the KD may promote a Th1 type 
tumor-reactive immune response. Additionally, we previously demonstrated that the KD 
reduces activation of the pro-inflammatory transcription factor, nuclear factor kappa B 
(NF-κB) and reduces expression of cyclooxygenase-2 (COX-2) [61, 62], both of which 
have been implicated in hypoxia-driven immunosuppression [132]. Taken together these 
studies led us to hypothesize that the KD may alter the tumor microenvironment to 
alleviate immune suppression and enhance anti-tumor immunity. 
In this study we investigated the role that an unrestricted KD plays in alleviating 
tumor immune suppression in a mouse model of malignant glioma. We studied the direct 
effects of the KD on total infiltration and function of tumor-reactive T cells and natural 
killer (NK) cells, as well as the indirect benefits of the KD on alleviation of immune 
suppression in the tumor microenvironment. 
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RESULTS 
 
KD enhanced survival is mediated by CD8+ T cells.  
 
Tumor bearing animals maintained on the ketogenic diet (KD) had a greater 
median survival when compared to animals fed a standard diet (SD) (Figure 4A). In 
order to effectively evaluate the importance of tumor-reactive CD8+ T cells in slowing 
tumor progression, CD8+ T cells were depleted from immune competent albino C57BL/6 
mice bearing tumors. There was a significant decrease in survival of mice depleted of 
CD8+ T cells prior to tumor cell inoculation in comparison to wild type mice maintained 
on SD (Figure 4B). In order to determine the importance of CD8+ T cells in the anti-
tumor effects of the KD, CD8+ T cell depleted animals were treated with the KD and 
survival was measured. Although the KD significantly improved survival in immune intact 
mice when compared to those maintained on SD, that difference in survival is lost when 
CD8+ T cells are depleted and mice are treated with the KD in comparison to immune 
intact mice fed SD (Figure 4C). Furthermore, the KD significantly increased survival in 
immune intact mice when compared to CD8 depleted mice fed KD (Figure 4D). Analysis 
of bioluminescence data also shows slower tumor growth in animals treated with KD 
when compared to SD in both immune competent and CD8 depleted mice (Figure 4E).  
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Figure 4: Enhanced survival with the ketogenic diet is mediated in part by CD8 T 
cells. Kaplan-Meier survival curves for ketogenic diet (KD) versus standard diet (SD) 
(A), SD versus SD + CD8 depletion (B), SD versus KD + CD8 depletion (C), KD versus 
KD + CD8 depletion (D). Bioluminescent tumor signals plotted as in vivo photon count 
versus days post-implantation (E). N=12 for immune competent mice; N=5 for CD8 
depleted mice; Log-rank (Mantel-Cox) test; p-values indicated on graphs.  
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The KD enhances immune cell infiltration, and increases the ratio of tumor-reactive 
CD4+ T cells to Treg ratio. 
 
To evaluate the effects of the KD on immune cell infiltration into the tumor, 
amounts of tumor-infiltrating  CD8+, CD4+, CD4+FoxP3+, and NKp46+CD3- cells were 
tested. There was no significant difference in the percentage of tumor-infiltrating CD8+ T 
cells between mice fed the KD and the SD (Figure 5A). However, mice fed the KD had a 
significant increase in the percentage of CD4+ T cells infiltrating the tumor in comparison 
to SD (Figure 5B). This increase in the percentage of CD4+ T cells was not due to an 
increase in the percentage of FoxP3+CD4+ T regulatory (Treg) cells (Figure 4C), and 
therefore the ratio of CD4+ T cells to Treg cells is significantly increased in tumors from 
mice fed a KD (Figure 5E).  In comparison, the CD8+ T cell to Treg cell ratio remained 
unchanged when comparing the two treatment groups (Figure 5D). Lastly, there was no 
difference in the percentage of tumor-infiltrating NK cells in tumors from mice fed a KD 
compared to SD (Figure 5F). Similar results were found when looking at the total number 
of infiltrating cells (data not shown). Therefore, the KD enhances CD4+ T cell presence 
at the tumor site, and this increase is not associated with an increase in the T regulatory 
cell subset.  
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Figure 5: CD4+ T cell infiltration increases in mice fed the KD, without increases in 
Treg cell numbers. Flow cytometry analysis was performed to assess the cell types 
infiltrating tumors from mice fed both SD and KD. CD8 T cells (A), CD4 T cells (B) and 
CD4+FoxP3+ T regulatory cells (C) were assessed. The ratio of CD8 T cells to T 
regulatory cells (D) and CD4 to T regulatory cells (E) were determined.  The percent of 
infiltrating NKp46+CD3- natural killer cells were also assessed. N=5; student’s two-tailed 
t-test; ***p<0.001; ****p<0.0001. 
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The KD influences expression of immune inhibitory receptors on tumor-infiltrating 
lymphocytes, and immune inhibitory ligands on glioma cells.  
 
Tumor cell expression of immune inhibitory checkpoint proteins is a major 
mechanism by which tumors limit the efficacy of immune responses in vivo. To examine 
the influence of the KD on immune inhibitory checkpoints we evaluated changes of 
immune inhibitory receptor expression on CD8+ tumor-infiltrating lymphocytes (TILs), 
and changes in expression of inhibitory ligands on the tumor cells. Mice fed the KD had 
significantly reduced expression of two inhibitory ligands, PD-1 (Figure 6A) and CTLA-4 
on CD8+ TILs (Figure 6B). Additionally, mice fed the KD had reduced expression of 
CD86 (Figure 6C) and PD-L1 (Figure 6D) on the tumor cells. This suggests that the KD 
may alter tumor-mediated T cell suppression by reducing the number of cells that are 
susceptible to inhibition through the PD-1 and CTLA-4 inhibitory pathways.   
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Figure 6: The ketogenic diet reduces expression of immune inhibitory receptors 
and ligands expressed in glioma tumors. Expression of the immune inhibitory 
receptors, PD-1 (A) and CTLA-4 (B) on infiltrating CD8 T cells isolated from tumors from 
mice fed each diet were assessed. Expression of the immune inhibitory ligands, CD86 
(C) and PD-L1 (D), on GL261-Luc2 tumor tissue was also assessed. N=5; student’s two 
tailed t-test; *p<0.05; **p<0.01; ****p<0.0001.   
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The KD enhances innate and adaptive tumor specific immune function against glioma 
cells.  
 
To evaluate the influence of the KD on tumor-reactive immune cells at the tumor 
site, immune cell function from TILs removed from the tumor site at time of necropsy 
was tested. Intracellular cytokine staining following stimulation with tumor cells showed 
that when compared to SD, the KD significantly increases the ability of tumor-reactive 
CD8+ T cells to produce interferon gamma (IFN-γ), tumor necrosis factor (TNF), and 
interleukin 2 (IL-2) when stimulated with GL261-Luc2 cells (Figure 7A). Additionally, the 
KD significantly increased cytotoxic capabilities of tumor-reactive T cells from mice when 
compared to SD (Figure 7B). The function of T regulatory cells was also assessed by 
intracellular cytokine staining for interleukin 10 (IL-10). Although we did not find a 
difference in the number of tumor-infiltrating Tregs, those found in the tumors from 
animals fed the KD produced significantly less IL-10 in response to GL261-Luc2 cells 
when compared to animals maintained on SD (Figure 7C). Lastly, we studied natural 
killer (NK) cell function and found that tumor-infiltrating NK cells from mice fed the KD 
produce significantly more  IFN-γ and TNF in response to GL261-Luc2 cells than the 
cells isolated from SD fed animals (Figure 7D). Whether through direct interaction with 
immune cells, or through alleviation of tumor immune suppression in the 
microenvironment, the KD significantly enhances tumor-reactive immune function.  
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Figure 7: The ketogenic diet significantly enhances tumor-reactive CD8+ T cell and 
NK cell activity. Tumor-infiltrating lymphocytes (TILs) isolated from gliomas from mice 
fed KD versus SD were cultured alone (white bar) or in the presence of GL261-Luc2 
tumor cells (black bar) to access activity. Analysis of IFN-γ, TNF and IL-2 production in 
tumor-infiltrating CD8+ T cells was performed (A). Cytotoxic capability of CD8+ T cells 
isolated from tumors was assessed following exposure to GL261-Luc2 cells (B). IL-10-
production in CD4+FoxP3+ T regulatory cells was also assessed in response to 
stimulation with GL261-Luc2 cells (C). IFN-γ and TNF production in the infiltrating 
NKp46+CD3- natural killer cells isolated from tumors were assessed (D). N=5; student’s 
two-tailed t-test between the antigen-challenged SD and KD groups only; *p<0.05; 
**p<0.01; ***p<0.001. 
  
  31 
The KD enhances innate and adaptive tumor-reactive immune responses indirectly via 
alleviation of immune suppression. 
 
To determine if the KD specifically enhances TIL function in the tumor 
microenvironment or alters global immune status, the effects of the KD on immune 
responses to two strains of Lymphocytic Choriomeningitis Virus (LCMV) was examined. 
Non-tumor bearing mice were infected with either LCMV Armstrong or Clone 13, and 
CD8 T cell function was accessed at Day 6 and 30. There was no significant difference 
in cytokine production by CD8+ T cells responding to either LCMV dominant epitopes, 
GP33 or NP396 (Figure 8A) at either time point or with either infection regardless of diet. 
Additionally, there was no significant difference in the percentage of PD-1+CD8+ T cells 
between KD and SD fed mice (Figure 8B). Although the KD did not alter CD8 function 
against acute and chronic viral infections, it did alter immune mediated killing at the 
tumor site suggesting alleviation of immune suppression is specific to the tumor 
microenvironment. 
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Figure 8: The ketogenic diet had no effect on T cell activity in an acute and 
chronic mouse model of LCMV infection. Splenocytes from non-tumor bearing mice 
infected with LCMV Armstrong or Clone 13 were isolated at day 6 and 30, and 
stimulated with GP33 or NP396 antigens. IFN-γ+TNF+CD8+ cells in mice fed SD versus 
KD (A). PD-1+CD8+ expression in mice fed SD versus KD (B). N=5 in each group. 
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DISCUSSION 
Activated effector immune responses against glioblastoma multiforme (GBM) 
may provide benefits in patient survival; however these tumors exert a variety of 
immunosuppressive pressures on the surrounding microenvironment [133, 134]. These 
include increased induction of CD8+FOXp3+ regulatory T cells (Tregs), elevated 
immunosuppressive cytokine levels, diminished CD4+ helper T cell populations, 
tolerized antigen presenting cells and upregulated immune inhibitory checkpoints [115]. 
For example, Tregs suppress immune responses by secreting cytokines such as IL-10 
and facilitating inactivation of CD8+ cytotoxic T cells by direct cell-to-cell interactions 
[135]. A key observation in immunosuppressed GBM patients is a decrease in CD4+ T 
cells with an increased proportion of Tregs and increased IL-10 levels [115, 136]. The 
current study demonstrated that tumors from animals maintained on the KD had a 
significantly increased CD4+ T cell population and a decreased proportion of Tregs 
when compared to control animals. Further the Tregs isolated from animals maintained 
on the KD produced significantly less IL-10 when stimulated with tumor cells. Similar 
results were demonstrated in a study using a pancreatic cancer model which showed 
increased CD4+ T cells and decreased Tregs when animals were fed a KD [137].  
In addition to increasing Tregs and IL-10 production in the microenvironment, 
tumors exploit immune inhibitory signaling pathways involving direct cell-to-cell 
interactions. Key mediators of this system include cytotoxic T-lymphocyte-associated 
protein 4 (CTLA-4) and programmed death-1 (PD-1) which are found on the surface of 
activated effector T cells and act as checkpoints to regulate immune proliferation and 
activation. For example, when PD-1 binds its ligand, programmed death ligand 1 (PD-
L1), activated CD8+ and CD4+ T cells are suppressed [118]. Increased PD-L1 
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expression has been observed on tumor cells and immune cells within the GBM 
microenvironment [119-122] and leads to direct inactivation of CD8+ T cells [71, 123]. 
The current study demonstrates significantly decreased expression of PD-1 and CTLA-4 
on tumor-infiltrating CD8+ T cells and decreased expression of their ligands (PD-L1 and 
CD86, respectively) on dissociated tumor cells from animals maintained on the KD when 
compared to control animals. Blockade of the CTLA-4 and PD1 immune checkpoints 
represents a potentially important anti-glioma strategy that has proven effective in 
preclinical models of glioma [138-142] and has warranted exploration in ongoing clinical 
trials [143].   
The current study suggests that the KD may shift the immunological landscape 
from inflammatory, non-protective immune responses to cytotoxic Th1 responses and 
promotion of immune mediated killing at the tumor site. Shifting the balance toward a 
Th1 immune response leads to a general change in cytokine milieu at the tumor site 
which alters antigen presenting cell maturation and amount of overall immune cell 
activation [144-149].  This may explain results seen in this manuscript including 
increased NK and CD8+ T cell function, changes in CD4+ T cell recruitment, reduction in 
immune inhibitory receptor expression, and ligand availability on the tumor cells 
themselves. It should be noted that increased CD4 to CD8 T cell ratio may be indicative 
of a Th2 type immune response at the tumor site [150], which may promote an immune 
tolerance state; however, greater CD8 T cell activation in the tumors from mice 
maintained on a KD suggests this is not the case. 
It is known that activated T cells undergo metabolic reprogramming in which 
glycolysis is required to support proliferation and efficient growth [151-154]. Recent 
evidence also suggests that reduced glucose availability and increased fatty acid 
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oxidation favors T regulatory cells over effector T cells [155]. However, tumor-infiltrating 
T cells from mice fed the KD are still able to mount effective responses, undergo 
appropriate differentiation, and retain function even with the characteristic drop in 
glucose availability that accompanies the KD. It is currently unclear how the KD alters 
the metabolic activity of lymphocytes and why this effect appears to be specific to the 
lymphocytes isolated from the tumor microenvironment. It is possible that T-cells can 
utilize ketones as a primary energy source in place of glucose in a way similar to that of 
normal cells in the brain [32, 34]. Recent work has suggested that tumor cells may 
outcompete other cells in the microenvironment for glucose and other nutrients, thereby 
reducing the activation of anti-tumor effector T cells [156, 157]. By providing ketones as 
an alternative energy source for lymphocytes it can be postulated that the KD may 
alleviate immunosuppression mediated by nutrient competition. Further studies are 
needed to explore this question and determine the precise role of ketones in T cell 
metabolism.  
While the effect of the KD on tumor-infiltrating lymphocytes has only recently 
been explored, existing preclinical in vitro and in vivo data as well as case reports and 
anecdotal information have generated increased support for clinical testing. This is 
supported strongly by our preclinical data demonstrating that the KD, when given in 
combination with radiation, dramatically enhances survival when compared to radiation 
treatment alone [80]. The mechanisms underlying this effect are still under investigation; 
however, as radiation-induced tumor killing is known to expose the immune system to a 
greater diversity of tumor antigens, increased antigen processing, and increased 
immunogenic cytotoxicity it is possible that the KD as an adjuvant can work to augment 
the effect of radiation in part by enhancing immunity against GBM.  
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In summary, the KD may work as an immune adjuvant in the glioma 
microenvironment by reducing immune suppression, and promoting Th1 type immune 
responses against the tumor. These data provide additional support for the use of the 
KD in combination with the current standard of care and newer therapies for the 
treatment of brain tumors. 
 
METHODS 
Antibodies and cell lines 
Fluorochrome-conjugated anti-mouse monoclonal antibodies (Abs) specific for 
CD8α, CD274, CD279, CTLA-4, CD86, tumor necrosis factor (TNF), interferon gamma 
(IFN-γ), interleukin-2 (IL-2), CD4, FoxP3, NKp46, CD3, and interleukin-10 (IL-10) were 
purchased from eBiosciences (San Diego, CA) and diluted 1:200 prior to use. Anti-CD8 
depletion antibodies were purified from the mouse 2.43 hybridoma cell line purchased 
from ATCC (Manassas, VA). Bioluminescent GL261-Luc 2 cells were derived and grown 
as previously described [80].  
Mice and tumor implantation 
GL261-Luc2 cells were harvested by trypsinization, washed and resuspended at 
a concentration of 1–2x107 cells/ml in DMEM without FCS and implanted into ten week 
old B6 (Cg)-Tyrc-23/J (albino C57BL/6) mice (The Jackson Laboratory, Bar Harbor, ME) 
at an average weight of 19-20 grams as previously described [61, 80, 158]. Briefly, 
animals were anesthetized by an intraperitoneal injection of ketamine (10 mg/kg) and 
xylazine (80 mg/kg), placed in a stereotactic apparatus and an incision was made over 
the cranial midline. A burrhole was made 0.1 mm posterior to the bregma and 2.3 mm to 
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the right of the midline. A needle was inserted to a depth of 3 mm and withdrawn 0.4 mm 
to a depth of 2.6 mm. Two µl of GL261-luc2 cells (107 cells/ml) were infused over the 
course of 3 minutes. The burrhole was closed with bonewax and the incision was 
sutured. 
Treatment and Animal Monitoring 
Following implantation surgery, animals were fed standard rodent chow for 3 
days. Animals were then randomized to remain on standard diet (SD) or changed to a 
KD (KetoCal®; Nutricia North America, Gaithersburg, MD). The KD was obtained directly 
from the manufacturer and is a nutritionally complete diet providing a 4:1 ratio of fats to 
carbohydrates plus protein (72% fat, 15% protein, and 3% carbohydrate). The KD was 
prepared by mixing KetoCal® with water (2:1) and fed to the animals each day (ad 
libitum). Bioluminescence was analyzed to quantify tumor burden as described [80]. 
Serum β-hydroxybutyrate (BHB) and glucose levels were measured using a Precision 
Xtra® blood monitoring system (Abbott Laboratories, Abbott Park, IL). Animals were 
weighed every 3-5 days and euthanized upon occurrence of visible symptoms of 
impending death such as hunched posture, reduced mobility and weight loss [61, 159]. 
Measurements of animal body weight, blood BHB, and glucose were also performed 
(data not included). 
CD8 depletion in vivo 
Supernatant from 2.43 hybridoma cells was precipitated in saturated ammonium 
sulfate to 45% (v/v) overnight at 4°C and dialyzed against PBS for 24 hrs. The 
concentration of dialyzed antibody was determined by UV spectroscopy, and 0.3 mg of 
purified antibody was administered via intraperitoneal injection twice before tumor 
inoculation (day -5 and -3), and continued every three days after inoculation until 
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euthanasia. CD8 T cell depletion was confirmed by flow cytometry analysis of peripheral 
blood mononuclear cells, as previously described [160].  
Tissue preparation 
When mice became symptomatic they were anesthetized with 80mg/kg 
ketamine, 10 mg/kg xylazine followed by cardiac perfusion with ice-cold RPMI media just 
prior to euthanization. Tumor tissue and non-tumor contralateral brain were collected in 
RPMI media and run through a 70µm filter. Tumor-infiltrating cells were isolated from 
tumor tissue by centrifugation over a 30/70% Percoll gradient (Sigma-Aldrich, St. Louis, 
MO) before antibody staining and analysis of cell populations on an LSRFortessa flow 
cytometer (BD Biosciences, San Jose, CA). Flow cytometry data were analyzed with 
FlowJo8.8 (Tree Star Inc., Ashland, OR) and graphs were generated using Prism 5 
software (GraphPad Software, La Jolla, CA).  
Intracellular cytokine staining 
Lymphocytes were cultured alone or stimulated with GL261-Luc2 cells at a 
density of 106 cells per well (6-well plate). GolgiStop (BD Biosciences) was added at 1 
hour to inhibit export of cytokines and after a further 5 hours of incubation, cells were 
stained for extracellular proteins. Permeabilization and intracellular staining for cytokines 
was done according to manufacturer’s instructions using the Cytofix/Cytoperm kit (BD 
Biosciences).  
Cytotoxicity ELISA 
Lymphocytes were isolated from tumor tissue, and cultured alone or with GL261-
Luc2 cells at varying effector to target cell ratios. Lactate dehydrogenase (LDH) ELISA 
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was performed using CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega, 
Madison, WI). Absorbance was recorded at 490nm. 
Animals and virus 
Six to 8-week-old female C57BL/6 mice were obtained from The Jackson 
Laboratory. All experiments were conducted under Arizona State University IACUC 
approval and followed all relevant federal guidelines and institutional policies. The 
Armstrong and clone 13 strains of Lymphocytic Choriomeningitis Virus (LCMV) were 
grown as previously described [161]. Mice were infected with 2 x 105 PFU of LCMV 
(Armstrong) injected intraperitoneally or 2 x 106 PFU of LCMV (clone 13) injected 
intravenously. 
Statistical Methods  
Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software, San 
Diego, CA). All values are represented as the mean ± SD and significance was 
determined using both the Student’s t- test and the Mann Whitney non-parametric test. P 
< 0.05 was considered statistically significant.  For the Kaplan Meier survival data the 
log-rank (Mantel-Cox) test was used to assess statistical significance. 
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CHAPTER 3 
 
THE KETONE BODY BETA-HYDROXYBUTYRATE INHIBITS HISTONE 
DEACETYLASES AND SENSITIZES MALIGNAT GLIOMNA CELLS TO RADIATION  
 
INTRODUCTION 
 
Despite decades of innovative research, glioblastoma multiforme (GBM) remains 
a uniformly lethal disease. Radiotherapy is the most effective non-surgical therapy for 
GBM; however these tumors often recur, lending to the dismal prognosis for this 
disease. Resistance to radiation and is considered a major driver of recurrence in GBM 
and other cancers and thus has sparked great interest in the development of new 
therapeutic strategies that enhance radiation.  
An adjuvant strategy for malignant glioma being developed in our laboratory 
involves using a therapeutic ketogenic diet (KD). Our previously published studies 
demonstrate enhanced survival and alterations in major pathways involved in glioma 
growth and progression when glioma-bearing mice are fed an unrestricted KD and [61, 
62, 80, 127]. Other groups have demonstrated anti-proliferative effects using alternative 
methods to increase ketones and reduce glucose including caloric restriction and/or 
restricted ketogenic diets in experimental mouse and human brain tumor models [79]. 
While these studies provide important insight into the mechanisms underlying the anti-
tumor effects of the KD alone, clinically this treatment is not likely to be given without 
standard of care consisting of radiation and temozolomide chemotherapy. We therefore 
investigated the impact of the KD on radiation in vivo. Using a bioluminescent, syngeneic 
intracranial model of malignant glioma (GL261-Luc2), the KD was shown to significantly 
potentiate the anti-tumor effect of radiotherapy [80]. In this study, 9 out of 11 animals 
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maintained on the KD and treated with radiation had complete and sustained remission 
of their implanted tumors, even after being switched back to a standard rodent diet 
(Figure 2). To our knowledge this is the only study investigating the effects of the KD as 
an adjuvant to radiation in glioma, warranting further exploration into the radiosensitizing 
mechanisms of the KD.  
It has recently been shown that β-hydroxybutyrate (BHB) can act as a histone 
deacetylase inhibitor (HDACi) [53]. The epigenetic changes that occur with inhibition of 
HDACs are being looked at for cancer therapy; and HDAC inhibition can sensitize tumor 
cells to radiation and chemotherapy [162-165]. These studies along with the finding that 
BHB acts as an HDAC inhibitor, suggest that this may be an important, but overlooked, 
mechanism through which the ketogenic diet exerts some of its anticancer effects and 
enhances radiation. Further, accumulating experimental evidence shows that radiation 
induces immunogenic cell death and promotes recruitment and function of T cells within 
the tumor microenvironment [166-168]. So understanding the radiosensitizing 
mechanisms underlying the KD may also help us understand its role as an immune 
adjuvant.  
 In this study we investigated the role BHB plays in radiosensitization. We 
examined the ability of BHB to inhibit HDACs and radiosensitize malignant glioma cells 
to radiation in vitro. We also examined the impact of BHB on DNA damage repair in 
these cells. The overall goal of this study is to define the role BHB plays in 
radiosensitivity with the aim of better understanding the mechanisms underlying the KD 
as an adjuvant to radiation therapy. 
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RESULTS 
 
BHB sensitizes mouse malignant glioma cells to radiation 
 
To assess the impact of BHB on radiation sensitivity in vitro, GL261-Luc2 cells 
were treated with 2, 5 and 10mM BHB with or without one dose of 2 Gy radiation. 
GL261-Luc2 cells treated with 5 and 10mM BHB alone showed significantly reduced 
proliferation while treatment with 2mM BHB alone showed no significant changed 
compared to mock (Figure 9). However, all three doses of BHB when combined with 2 
Gy radiation significantly reduced proliferation compared to radiation treatment alone 
(Figure 9).  
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Figure 9: BHB enhances radiation against glioma cells in vitro. GL261-Luc2 cells 
were treated with 2, 5 and 10 mM BHB for 48 hours prior to treatment with 2 Gy 
radiation. Cells were counted every 48 hours and BHB was replenished every 24 hours 
throughout the experiment (N=3).  
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BHB treatment leads to increased accumulation of DNA damage  
 
To determine the impact of BHB on DNA damage, the expression of the double-
stranded DNA break marker, γ-H2AX, was assessed. GL261-Luc2 treated with 5mM 
BHB showed a significantly higher level of γ-H2AX expression at 1 hour post radiation 
(Figure 10). Interestingly BHB without radiation causes a slight increase in DNA damage 
although this was not statistically significant. This is a phenomenon observed in other 
studies and may be related to the genomic instability of cancer cells and the ability of 
HDACi to slow cell cycle progression [169-171]. 
 
  
  45 
 
Figure 10: BHB increases radiation-induced DNA damage in vitro. GL261-Luc2 cells 
were treated with 5 mM BHB for 24 hours prior to treatment with 4 Gy radiation. Protein 
was isolated 1 hour following radiation and western blotting was used to assess levels of 
the DNA double stranded break marker γ-H2AX. Expression is normalized to B-actin and 
expressed as a fold change from mock treated cells (N=3; t-test; *p<0.05).  
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BHB significantly increases acetylation of histone H3  
  
To validate the ability of BHB to inhibit HDACs, acetylation of histone H3 was 
assessed in BHB-treated GL261-Luc2 cells. Treatment with 5mM BHB alone lead to the 
significant increase in acetylated histone H3 when compared to mock treated cells 
(Figure 11). Radiation alone increased acetylation compared to mock treated cells. 
Further, 5mM BHB combined with 4 Gy radiation led to significantly increased 
acetylation compared to radiation alone (Figure 11).      
  
  47 
 
Figure 11: BHB increases acetylation of histone H3 in vitro. GL261-Luc2 cells were 
treated with 5 mM BHB for 24 hours prior to treatment with 4 Gy radiation. Protein was 
isolated 1 hour following radiation and western blotting was used to assess levels of 
acetylated histone H3. Expression is normalized to B-actin and expressed as a fold 
change from mock treated cells (N=3; t-test; *p<0.05). 
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BHB treatment leads to an increase of cells in the G2 phase of the cell cycle 
 
The different phases of the cell cycle can greatly impact radiosensitivity [172]. To 
determine the impact of BHB on the cell cycle progression, cell cycle analysis was 
performed on GL261-Luc2 cells following treatment with 5mM BHB and 4 Gy radiation. 
BHB alone reduced the percentage of cells in the G1 and increased the percentage of 
cells in G2 phase, which is considered the most radiosensitive phase (Figure 12). There 
were similar trends found in the cells treated with both 5mM BHB and 4 Gy radiation; 
however, only the difference in G1 phase cells was statistically significant when 
compared to radiation treatment alone.  
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Figure 12: BHB increases G2 arrest in glioma cells in vitro. GL261-Luc2 cells were 
treated for 48 hours with 5mM BHB prior to treatment with 4 Gy radiation. At 24 hours 
post-radiation cells were fixed and stained with DAPI. Flow cytometry was performed to 
determine the cell cycle distribution (N=3; t-test; *p<0.05).  
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BHB reduces the expression of RAD51 and other DNA damage repair proteins in a 
dose-dependent manner 
  
Many studies have demonstrated that HDAC inhibition can alter DNA damage 
repair pathways in cancer cells [171]. To determine the impact of BHB on DNA damage 
repair pathways, the expression of various proteins involved in DNA damage repair was 
assessed. BHB treatment significantly decreased the expression of MRE11, KU70 and 
RAD51 when compared to mock treated cells (Figure 13). This corresponded with a 
dose-dependent increase in acetylation of histone H3.  
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Figure 13: BHB reduces expression of DNA damage repair proteins. GL261-Luc2 
cells were treated with 5 mM BHB for 24 hours prior to protein isolation and western 
blotting analysis was performed using antibodies against MRE11, KU70, RAD51 and 
acetyl-histone H3. B-actin was used a loading control (experiment repeated in duplicate).  
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Knockdown of HDAC1, HDAC2 and HDAC3 lead to a decrease in RAD51 expression 
   
BHB is a known class I HDAC inhibitor [53]. To determine the impact of class I 
HDACs on RAD51 expression, cells were transfected with siRNAs targeting HDACs 1-3. 
Knockdown of HDAC1, HDAC2, and HDAC3 each led to the significantly reduced 
RAD51 protein expression in GL261-Luc2 cells (Figure 14A). Knockdowns were 
confirmed using western blot analysis (Figure 14B).  
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Figure 14: Knockdown of Class I HDACs downregulated expression of RAD51. 
GL261-Luc2 cells were transfected with siRNAs targeting Hdac1, Hdac2, and Hdac3 or 
non-targeting siRNAs (siNT) as a control for 72 hours prior to protein isolation. (A) 
Western blotting analysis was performed using an antibody against RAD51 and 
expression was normalized to B-actin (N=3; t-test; **p<0.01; ***p<0.001). (B) 
Knockdowns were confirmed using western blot analysis. 
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The ketogenic diet reduces expression of RAD51 in vivo 
  
Evidence suggests that several changes elicited by a ketogenic diet (KD) may be 
due in part to the action of BHB. To determine if the BHB-induced changes in RAD51 
expression in vitro are also found in vivo, expression in tumor tissue from animals 
maintained on the KD was assessed. Tumor tissue from GL261-Luc2 tumor-bearing 
mice maintained on the KD shows a significantly decreased expression of RAD51 when 
compared to mice fed a standard rodent diet (SD)(Figure 15).  
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Figure 15: RAD51 expression is reduced in tumors from animals maintained on 
the KD. Western blotting analysis was performed to assess RAD51 expression on tumor 
tissue from animals maintained on the ketogenic diet (KD) and compared to that from 
animals maintained on a standard rodent diet. Expression was normalized to B-actin and 
displayed as a fold change from SD (N=5 for KD; N=6 for SD; t-test; *p<0.05).  
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DISCUSSION 
 
Dysregulation of epigenetic modifications is a hallmark of many cancers including 
high grade gliomas [173]. Thus exploring agents that reverse these aberrant epigenetic 
changes has become a promising anti-cancer strategy [162, 174-176]. It has been 
postulated that the ketogenic diet (KD) may impact the epigenetic landscape due in part 
to the activity of the ketone body BHB to inhibit. Shimazu et al was the first to 
demonstrate that BHB inhibits activity of class I histone deacetylases (HDACs) leading 
to increased histone acetylation and gene expression changes in normal untransformed 
kidney cells [177]; however until now this has yet to be explored in the context of glioma. 
Several cancers including GBM, frequently overexpress HDACs, HDAC inhibition has 
can lead to cell cycle arrest, promote cellular differentiation and induce apoptosis [174, 
178]. Although HDAC inhibitors can impact several different pathways in gliomas [178], it 
has been demonstrated that that Class I HDAC inhibitors can impair DNA damage repair 
[171]. The current study is the first to validate the HDAC-inhibiting activity of BHB in 
glioma cells and demonstrate its ability to impact DNA damage repair.  
DNA damage repair mechanisms play a key role in the radioresistance of GBM 
[179]. For example, RAD51 is crucial for homologous recombination repair of double-
stranded DNA breaks and is overexpressed in several human cancers including GBM 
[180, 181]. The increased expression of RAD51 in cancer leads to resistance to double-
stranded break inducing anti-cancer therapies [182-184]. A variety of studies have 
demonstrated that Rad51 inhibition is in effective radiosensitizing strategy for malignant 
glioma [185-188]. The current study found that BHB significantly reduced the expression 
of proteins involved in DNA damage repair including RAD51. Further, recent studies 
have highlighted RAD51 as an effective target for glioma stem cells as well [189-191], 
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which represent a therapy-resistant population in GBM tumors [192]. We also 
demonstrated that BHB increases radiosensitivity and decreases expression of RAD51 
in human glioma stem cells [193]. Thus BHB-mediated downregulation of RAD51 may 
represent an important radiosensitizing mechanism underlying ketogenic therapy and 
may help explain our previously published in vivo results [80].  
The ability of HDAC inhibitors to impact expression of proteins involved with DNA 
damage repair is well supported in the literature. Various HDAC inhibitors have been 
demonstrated to down-regulate Rad51 in a variety of cancers including pancreatic [194], 
melanoma [195], acute myeloid leukemia [196], esophageal [197], and colon [198]. 
However, many of these pharmacological agents have shown some toxicity and limited 
efficacy making translation into the clinical setting a challenge [171, 174, 199-202]. The 
current study shows that tumors in glioma-bearing mice maintained on a ketogenic diet 
(KD) have reduced expression of RAD51. To our knowledge this study is the first to 
show therapeutically relevant changes that occur due to a non-pharmacologic 
intervention such as the KD. 
HDAC inhibitors are not only being explored for their radiosensitizing capabilities 
but studies also suggest that they may modulate the immune system. For example, one 
study found that that the HDAC inhibitor trichostatin A improved the immune response in 
a glioma model by enhancing the function of natural killer (NK) cells [203]. In Chapter 2, 
we demonstrated that NK cells isolated from tumors maintained on the KD showed 
increased production of IFN-γ and TNF suggesting increased function. There are now 
multiple studies in a variety of cancers suggesting that HDAC inhibition is 
immunomodulatory and may enhance the efficacy of immunotherapy including PD-1/PD-
L1 blockade [204-208]. This suggests that the HDAC inhibiting properties of BHB may 
also enhance the immune system and may shed light on the immune enhancing 
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properties of the KD introduced in Chapter 2. Future studies specifically connecting 
these epigenetic mechanisms with the immune system and immunotherapy in the 
context of the KD are warranted.  
The results in this study lend to the growing body of evidence suggesting that in 
the absence of glucose restriction, BHB has anti-tumor benefits on its own. In addition, it 
provides a potential mechanism underlying the potent radiosensitizing capabilities of the 
KD demonstrated in our previously published preclinical study. This becomes crucial as 
more clinical trials are exploring the KD as an upfront therapy with radiation and 
chemotherapy. Finally, as radiation is known to act in synergy with the anti-tumor 
immune response and may enhance immunotherapies [166, 168], the current study also 
suggests that KD and BHB may further enhance the anti-tumor immune response by 
augmenting the effect of radiation. Taken together these data provide further support for 
the use of the KD as a pluripotent adjuvant treatment for malignant glioma and may help 
inform its clinical use.   
 
 
METHODS 
 
Cell Culture 
GL261-Luc2 cells (mouse malignant glioma) are grown in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal calf serum (FCS). Cells are incubated at 
37°C and 5% CO2. 
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Treatments 
 
(R)-(-)-3-Hydroxybutyric acid, sodium salt (BHB; Sigma-Aldrich, St. Louis, 
Missouri) was dissolved in media and replenished every 24 hours for growth assays. 
Radiation was administered with an RS 2000 Biological Irradiator (Rad Source 
Technologies Inc., Suwanee, GA) at 2.287 Gy/Min for varying times to attain desired 
dose.   
 
Growth Assays 
 
GL261-Luc2 murine glioma cells were seeded at 3.5 X 104 cells/well in 12-well 
culture plates with 5mM BHB. The cultures were seeded with BHB 24 hours prior to 
irradiation. Cell counts were obtained every 48 hours for 192 hours. To count each well, 
the cells were trypsinized, combined with Trypan Blue (Life Technologies, Carlsbad, CA) 
and counted using a Countess® automated cell counter (Life Technologies). 
 
 
 
Western Blotting  
 
Protein was extracted from cells using RIPA buffer (Cell Signaling Technology). 
Protein concentrations were determined using the Pierce BCA protein assay kit (Thermo 
Scientific, Rockford, IL, USA). All primary antibodies used were from Cell Signaling 
Technology and were diluted 1:1000 in blocking buffer prior to use. Secondary 
antibodies were purchased from Licor Biosciences and were used at a dilution of 
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1:15,000. Images were obtained using a Licor Odyssey Fc imager and data was 
analyzed using the Licor Image Studio software.   
 
Cell Cycle Analysis 
 
GL261-Luc2 cells were seeded in a 6-well culture plate at 1.5 x 104 cells/mL. 
Cells were treated with 5 mM BHB for 48 hours prior to treatment with 4 Gy radiation. 
Twenty-four hours post-radiation cells were lifted with Accutase (Life Technologies, 
Carlsbad, CA), fixed in 70% EtOH, stained with 1.25µg/mL DAPI (BD Pharmingen, San 
Jose, CA), and analyzed by FlowJo v10 software. 
 
siRNA Knockdown Experiment 
 
GL261-Luc2 cells were transfected with 25 nmol mouse Hdac1, Hdac2, Hdac3, 
or non-targeting control siRNAs using using DharmaFECT 1 transfection reagent (all 
reagents from GE Dharmacon, Lafayette, CO). After 72 hours of transfection protein was 
isolated and western blotting was performed as described above using antibodies 
against RAD51. Western blotting was used to confirm the knockdown of HDACs. 
Transfection conditions were optimized in GL261-Luc2 cells using lamin A/C control 
siRNAs from Dharmacon.  
 
Tumor Tissue for Western Blotting 
 
Mice were implanted with GL261-Luc2 cells and maintained on the KD or 
standard rodent diet as previously described in Chapter 2. On day 25 post-implantation 
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tumor tissue was harvested and snap frozen in liquid nitrogen. Tissue was homogenized 
in RIPA buffer and protein was isolated prior to western blotting analysis for RAD51 
expression (western blotting described above).  
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CHAPTER 4 
THE KETONE BODY BETA HYDROXYBUTYRATE REDUCES EXPRESSION OF PD-
L1 ON GLIOMA CELLS BUT DOES NOT IMPACT PD-1 EXPRESSION ON T CELLS 
 
INTRODUCTION 
 
The ketone body β-hydroxybutyrate (BHB) has traditionally been thought of as 
simply a metabolic substrate that replaces glucose during the ketogenic diet (KD), 
fasting or exercise; however, the effects of increased ketones go beyond simple 
considerations of energy availability [54, 209]. In vitro investigations demonstrated that 
BHB is able to recapitulate, in part, the in vivo effects of the full KD [50, 52]. This 
suggests that the ketone bodies themselves possess antitumor effects, and that perhaps 
the effects of the KD are mediated, at least in part, by the ketone bodies. Additional 
evidence for this comes from data showing that the use of ketone supplementation can 
enhance the effects of the KD and may even be effective in some diseases when used 
alone [59, 210-215].  
  Our laboratory’s investigations into the interactions between BHB and 
glioblastoma cells have revealed insights into the molecular basis for some of the KD’s 
effects, most notably its radio- and chemo-sensitizing effects. In vitro studies using BHB 
demonstrated that, even in the presence of high glucose, physiologically relevant doses 
of BHB reduced proliferation of several human glioblastoma cell lines, two human cancer 
stem cell lines, and a murine glioma cell line (unpublished data). In Chapter 3 of this 
dissertation we demonstrated the BHB radiosensitizes malignant glioma cells by 
inhibiting histone deacetylases and reducing expression of DNA damage repair proteins.  
Further, in a separate study BHB potentiated the chemotherapeutic agent 1,3-bis(2-
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chloroethyl)-1 nitrosourea (BCNU, carmustine) in a cell line derived from a recurrent 
human glioblastoma [50]. Taken together, these data suggest that ketone 
supplementation may provide an effective, less stringent alternative to the rigors of the 
KD; yet additional studies are needed to further develop this approach. 
It was demonstrated in Chapter 2 that the KD works in part as an immune 
adjuvant, boosting tumor-reactive immune responses in the glioma microenvironment by 
alleviating immune suppression in vivo.  In particular we found that KD reduced 
expression of programmed cell death-1(PD-1) on tumor-infiltrating T cells and its ligand 
PD-L1 on tumor cells. The PD-1/PD-L1 axis represents a crucial mechanism of glioma-
mediated immunosuppression and is a major focus of immunotherapy in GBM and other 
cancers [125]. The impact of BHB alone on this pathway is not yet understood and 
warranted the current study.      
In this study we found that BHB treatment significantly reduces expression of PD-
L1 on tumor cells which is consistent with our in vivo results. However; BHB failed to 
alter expression of PD-1 on T cells culture in vitro. These results suggest that BHB may 
play a key role in enhancement of anti-tumor immunity by KD but may not directly alter 
immune checkpoints in T-cells outside of the context of a tumor microenvironment. 
Taken together these results continue to increase our understanding of the mechanisms 
underlying the KD and specifically the role of BHB.   
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RESULTS 
 
BHB reduces expression of PD-L1 on malignant glioma cells 
 
To determine if BHB is plays a role in the downregulation of PD-L1 seen in vivo with the 
full KD, GL261-Luc2 mouse glioma cells were treated with BHB in vitro prior to analysis 
of PD-L1 expression. Western blotting analysis shows that 5mM BHB treatment 
significantly reduced PD-L1 expression in GL261-Luc2 cells when compared to mock 
treated cells (Figure 16).  
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Figure 16: BHB reduces expression of PD-L1 on mouse malignant glioma cells. 
GL261-Luc2 cells were cultured in 5mM BHB for 24 hours prior to protein isolation. 
Western blotting analysis shows significantly decreased expression of PD-L1 (N=3; t-
test; *p<0.05). 
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BHB does not impact activation of the PI3K pathway 
  
Studies have shown that PD-L1 expression in tumor cell can be regulated by the 
PI3K-AKT-mTOR pathway [120, 216]. To determine the impact of BHB on this 
mechanism, the key components of this pathway were analyzed in GL261-Luc2 cells 
following treatment with different doses of BHB. Western blotting analysis shows that 
5mM BHB did not significantly change the levels of phosphorylated PI3K, AKT or mTOR 
(Figure 17).  
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Figure 17: BHB does not significantly alter activation of the PI3K pathway. GL261-
Luc2 cells were treated with 0, 2, 5 and 10mM BHB for 24 hours prior to protein 
isolation. Western blotting analysis was performed to assess levels of phospho-PI3K 
(Tyr524), p-Akt (Ser473), p-mTOR (Ser2448). B-actin was used as a loading control and 
the experiment was run in duplicate. 
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BHB does not impact IFN-γ-induced PD-L1 expression 
  
Another mechanism of PD-L1 upregulation that has been described in glioma 
cells involves upregulation stimulated by interferon gamma (IFN-γ) [118]. The impact of 
BHB on this pathway was examined using GL261-Luc2 cells. Cells were treated with 
5mM BHB prior to treatment with IFN-γ. Cells were stained with PD-L1 antibody and flow 
cytometry was performed. As expected, IFN-γ treatment alone significantly increased the 
expression of PD-L1 compared to mock treated cells. However, pretreatment with BHB 
prior to IFN-y treatment showed no significant change in PD-L1 expression (as 
measured by mean fluorescent intensity) when compared to IFN-γ treatment alone. The 
cells not treated with IFN-γ confirmed the result from Figure 16 above, demonstrating a 
significant decrease in PD-L1 expression with BHB treatment when compared to mock 
treated cells (Figure 18). 
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Figure 18: BHB does not impact IFN-γ-mediated PD-L1 upregulation. GL261-Luc2 
cells were treated for 48 hours prior to treatment with IFN-γ (50 ng/mL) for 48 hours. 
Cells were stained with PD-L1 antibody and flow cytometry was performed. Experiments 
were run in triplicate and data is shown as representative histograms and mean 
fluorescent intensity of PD-L1 staining (N=3; t-test; ***p<0.001).  
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BHB does not impact PD-1, CTLA-4 or LAG3 expression on T cells 
 
In Chapter 2 we demonstrated that tumor-infiltrating CD8+ T cells from animals 
maintained on the KD had reduced expression of PD-1 and CTLA-4. To determine the 
impact of BHB on immune inhibitory checkpoint receptor expression, we used both 
CD8+ and CD4+ T cells isolated from P14 and SMARTA transgenic mice, respectively. 
T cells were treated with varying doses of BHB in vitro prior to flow cytometric analysis. 
There were no significant changes to PD-1, CTLA-4 or LAG-3 expression on either 
CD4+ or CD8+ T cells with any dose of BHB (Figure 19). Further, we found no 
significant changes in cell counts or viability in either T cell population following 
treatment with BHB (data not shown).  
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Figure 19: BHB does not impact immune checkpoint receptor expression in CD8 
or CD4 T cells. CD8+ (A) and CD4+ T (B) cells were isolated from P14 and SMARTA 
transgenic mice, respectively. Cells were activated with their cognate LCMV peptide and 
IL-2 and treated with 0, 2.5, 5, and 10mM BHB every 48 hours for 8 days. Flow 
cytometry was performed to analyze PD-1, CTLA-4 and LAG-3 expression. Experiments 
were run in triplicate and data is shown as a representative histogram for each treatment 
group. 
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Impact of BHB on cytokine production in T cells 
 
The ability to produce cytokines is a key indicator of effector function in T cells. In 
Chapter 2 we found that tumor-infiltrating CD8+ T cells from animals maintained on the 
KD produce significantly higher levels of IL-2, IFN-γ and TNF when stimulated with 
GL261-Luc2 cells. To assess the impact of BHB on cytokine production we again used 
CD8+ and CD4+ T cells isolated from P14 and SMARTA transgenic mice, respectively. 
T cells were treated with varying doses of BHB prior to analysis of cytokine levels in the 
media. In both CD8+ and CD4+ T cells there were no significant difference in levels of 
cytokines found in the media at any dose of BHB (Figure 20).  
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Figure 20: BHB does not alter secretion of cytokines by CD8+ and CD4+ T cells in 
vitro. CD8+ (A) and CD4+ T (B) cells were isolated from P14 and SMARTA transgenic 
mice, respectively. Cells were activated with their cognate LCMV peptide and IL-2 and 
treated with 0, 2.5, 5, and 10mM BHB every 48 hours for 8 days. On day 8, T cells were 
stimulated with IL-2, peptide and stimulator cells. A commercially available cytometric 
bead array (CBA) and flow cytometry was used to measure the presence of cytokines 
(IL-2, IL-4, IL-5, IFN-γ, and TNF) in the cell culture media. 
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DISCUSSION 
 
Upregulation of PD-L1 on tumor cells is a key factor in immune escape of 
gliomas. We previously demonstrated in Chapter 2 of this dissertation that glioma cells 
from mice maintained on KD exhibit decreased expression of PD-L1. There are two main 
mechanisms of upregulation: constitutively active oncogenic signaling pathways (“innate 
resistance”) and interferon gamma (IFN-γ) mediated upregulation (“adaptive 
resistance”). It was demonstrated that phosphatase and tensin homolog (PTEN) 
deficient glioma cells exhibit greater PD-L1 expression and that this is driven in part by 
the PI3K-AKT-mTOR pathway [120, 216]. In vivo studies have shown that the KD is 
capable of impairing the mammalian target of rapamycin (mTOR) signaling pathway in a 
mouse model of epilepsy [217] and a glioma stem cell xenograft model [218]. The 
current study found that that treating glioma cells with BHB in vitro reduced expression 
of PD-L1 (Figures 16 and 18) suggesting that BHB may in part be acting on constitutive 
signaling pathways. However, there was no difference in the levels of activated effectors 
in the PI3K-AKT-mTOR pathway. Literature suggests that other constitutive oncogenic 
signal pathways such as JAK/STAT3 and EGFR/MAPK can mediate intrinsic induction of 
PD-L1 expression in other cancer cell lines [125]. While the impact of BHB on these 
pathways has not been explored, they represent important avenues for future studies.  
IFN-γ is a proinflammatory cytokine produced mainly by activated T lymphocytes 
in response to antigen recognition during the adaptive immune response. Tumor-
infiltrating lymphocytes (TILs), in response to recognition of tumor antigens, produce 
IFN-γ which can drive expression of PD-L1 in tumor cells [125]. This mechanism of 
tumor-mediated immune evasion termed “adaptive resistance” is supported by a study 
demonstrating that treatment with IFN-γ increases the surface expression of PD-L1 in 
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several glioma cell lines [118]. Recent studies show that IFN-γ-induced expression of 
PD-L1 may rely on activation of nuclear factor kappa B (NF-κB) [219]. We previously 
demonstrated that tumors from animals maintained on KD exhibited decreased 
activation of NF-κB [62] suggesting a possible mechanism by which KD could impair 
adaptive upregulation of PD-L1 expression. Fu et al. demonstrated that BHB treatment 
decreased activation of NF-κB and production of other pro-inflammatory mediators in 
immortalized mouse microglia cells [220]. However, the current study found that there 
was no difference in IFN-γ-meditated upregulation of PD-L1 when cells were pretreated 
with BHB, although the impact of BHB on NF-κB was not examined. This study may be 
limited by the fact that only one dose of INF-γ (50 ng/mL) was tested. This dose is a 
relatively high dose selected from the literature and that increased the intensity of PD-L1 
expression in GL261-Luc2 cells 20-fold. It is possible that the effects of BHB on this 
pathway aren’t extremely potent and may have been masked by the high dose of IFN-γ. 
Future studies not only need to explore the impact of BHB with different concentrations 
of IFN-γ but should also assess regulators of this pathway such as NF-κB.  
Increased PD-1 expression is found on tumor-infiltrating T cells in multiple cancer 
types including glioma and indicates T cell exhaustion and reduced anti-tumor 
capabilities [221]. We previously demonstrated in Chapter 2 that tumor-infiltrating CD8+ 
T cells from animals maintained on KD showed decreased expression of PD-1, 
increased anti-tumor cytokine (IL-2, TNF, IFN-γ) production and greater cytotoxic 
capabilities (data not shown) when cultured with tumor cells as compared to T cells 
isolated from control animals [127]. This suggests that KD may reduce exhaustion and 
improve function in glioma-infiltrating T cells; however; the role of BHB in this process is 
unknown. 
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The current study demonstrates that BHB does not change expression of 
immune checkpoint receptors including PD-1 in either CD8+ or CD4+ T cells in vitro. PD-
1 expression can be regulated by a number of genetic and epigenetic mechanisms 
[221]. Studies show that high PD-1 expression on lymphocytes is sustained by high 
levels of FoxO1 transcription factor during chronic viral infection [222]. Conversely, the 
Tbet transcription factor antagonizes FoxO1 and inhibits expression of PD-1 [223]. It is 
possible that the KD shifts the balance away from FoxO1 expression and high PD-1 
expression which is likely to be found in a T-cell-exhausted, immunosuppressed tumor 
microenvironment. It is difficult to recapitulate these conditions in vitro which may 
represent a limitation to the model chosen for the current study. To approach this issue 
we cultured T cells for a week prior to treating with BHB for an additional week to 
simulate treatment of “late” activated T cells. However at the end of the experiment, 
viability and the number of cells were too low to obtain quality data. Future studies will 
focus on further defining the impact of the KD on mechanisms of PD-1 regulation in the 
tumor microenvironment and may only be appropriate with in vivo studies.  
In addition to the potential limitations of in vitro modeling mentioned above, it is 
also important to consider that these studies are using BHB treatment without the 
reduction of glucose. Although BHB has demonstrated anti-tumor benefits alone, the KD 
also elicits a decrease in blood glucose which may also contribute to the mechanisms 
discussed here. It is known that activated T cells rely heavily on glycolysis to support 
proliferation and efficient growth [151-154]. As discussed in Chapter 2, we do not yet 
know how this plays a role in the changes to T cells elicited by the KD, however; it may 
be appropriate to study the combination of reduced glucose with ketone treatment in 
future studies.  
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We previously demonstrated that the KD significantly alters PD-1 expression and 
cytokine production in tumor-infiltrating CD8+ T cells in vivo but did not elicit the same 
changes in a mouse model of acute and chronic LCMV infection [127]. This suggests 
that the impact of KD on lymphocytes may be specific to the tumor microenvironment 
and may help explain the results from the current study. It is has been shown that 
glioblastoma cells can secrete cytokines and other soluble factors that increase 
proliferation of T regulatory cells which can suppress anti-tumor immunity by inducing T 
cell anergy and apoptosis [224]. Evidence suggests that activation of NF-κB plays a key 
role in this ability of gliomas to manipulate the microenvironment [225]. Taken together 
with our data showing that KD reduces activation of NF-κB [62] this may provide an 
alternative explanation of KD-mediated influence on infiltrating lymphocytes.  
It is also likely that the impact of the KD and BHB extends beyond T cells. For 
example, we demonstrated that KD enhanced IFN-γ and TNF production in tumor-
infiltrating natural killer (NK) cells while reducing production of the immunosuppressive 
cytokine IL-10 in T regulatory cells [127]. Further, we found an increase in infiltrating 
CD4+ T cells but a decreased ratio of T regulatory cells (CD4+ FoxP3+) to CD4+ T cells 
in mice maintained on the KD compared to controls [127]. This decreased ratio reflected 
similar findings by Husain et al. in a study exploring KD in a pancreatic cancer model 
[226]. Though NK and T regulatory cells have important roles in the glioma 
microenvironment and may warrant further studies in the context of the KD and BHB, 
they are outside of the scope of this study. 
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METHODS 
 
Tumor Cell Culture 
 
GL261-Luc2 mouse malignant glioma cells were grown in Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 10% fetal calf serum. Cells were cultured at 
37oC in 5% CO2.   
 
In Vitro T Cell Model 
 
These experiments utilized both CD8+ and CD4+ T cells isolated from P14 and 
SMARTA transgenic mice, respectively. P14 mice are transgenic mice producing CD8+ 
T cells expressing T cell receptors specific for gp33-41 peptide from the lymphocytic 
choriomeningitis virus (LCMV). SMARTA mice are transgenic mice producing 
predominantly CD4+ T cells expressing T cell receptors specific for gp61-80 peptide 
from LCMV. This represents a simple well characterized in vitro model of T cell 
activation and function. These experiments were performed with the assistance and 
guidance of graduate student Kavita Manhas in Dr. Joseph Blattman’s laboratory at 
ASU. 
 
Treatments 
 
Cells were treated with sodium (R)-3-hydroxybutyrate (Sigma-Aldrich, St. Louis, 
MO) diluted in water and brought to a final concentration in cell culture media. GL261-
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Luc2 cells were treated with 50 ng/mL IFN-γ (Cell Signaling Technology, Danvers, MA) 
diluted in PBS.   
 
Western Blotting 
 
Protein was extracted from GL261-Luc2 cells using RIPA buffer (Cell Signaling 
Technology). Protein concentrations were determined using the Pierce BCA protein 
assay kit (Thermo Scientific, Rockford, IL, USA). Primary antibodies against PD-L1, 
phospho-PI3K (Tyr524), phospho-Akt (Ser473) and phospho-mTOR (Ser2448) (Cell 
Signaling Technology) were diluted 1:1000. Secondary antibodies were purchased from 
Licor Biosciences and were used at a dilution of 1:15,000. B-actin (Licor Biosciences, 
Lincoln, NE) was used as a loading control. Images were obtained using a Licor 
Odyssey Fc imager and data was analyzed using the Licor Image Studio software.    
 
 
Immune Inhibitory Checkpoint Receptor Expression  
 
CD8+ and CD4+ T cells were isolated from P14 and SMARTA transgenic mice, 
respectively. Cells were activated with their cognate LCMV peptide (1 µg/mL) and IL-2 
(1.25 x 10-5 µg/mL) and treated with 0, 2.5, 5, and 10mM BHB every 48 hours for 8 days. 
Flow cytometry was performed following staining of cells with CD4, CD8, PD-1, CTLA-4 
and LAG-3 antibodies (BD Biosciences, San Jose, CA). Viability and cell counts were 
recorded prior to flow cytometric analysis.  
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Cytometric Bead Array 
 
T cells were cultured as described above for 8 days with 0, 2.5, 5 and 10mM 
BHB treatment. On day 8, T cells were restimulated with peptide and IL-2 for 12 hours 
prior to isolating conditioned media. A commercially available cytometric bead array 
(CBA) and flow cytometry was used to measure the presence of Th1/Th2 cytokines (IL-
2, IL-4, IL-5, IFN-γ, and TNF) in the cell culture media. 
 
Flow Cytometry 
 
Analysis of cell populations and cytokine bead arrays were performed using an 
LSRFortessa flow cytometer (BD Biosciences, San Jose, CA). Flow cytometry data were 
analyzed with FlowJo10 (Tree Star Inc., Ashland, OR) and graphs were generated using 
Prism 7 software (GraphPad Software, La Jolla, CA).
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CHAPTER 5 
THE KETOGENIC DIET INCREASES THE EXPRESSION OF MICRORNAS 
PREDICTED TO TARGET PD-L1  
 
INTRODUCTION 
 
The upregulation of PD-L1 plays a large role in immune evasion by gliomas. As 
discussed in Chapter 4 there are multiple signaling pathways that can regulate PD-L1 
expression. This upregulation can be mediated by adaptive induction by interferon 
gamma (IFN-γ) and/or intrinsic induction by oncogenic signaling pathways; however 
additional mechanisms including responses to the hypoxic microenvironment and 
microRNA regulation have also been implicated [125]. Taken together the literature 
suggests complicated regulation of PD-L1 expression which warrants a further look at 
the impact of the ketogenic diet (KD) on these additional mechanisms.    
MicroRNAs (miRNAs) are short, non-coding RNA molecules that regulate gene 
expression by suppressing mRNA translation and reducing mRNA stability [9]. miRNA 
dysregulation has emerged as a crucial driver of cancer biology [227]. Alterations in 
miRNA processing machinery [228] and global reduction in expression of miRNAs [229] 
have been described in many cancers. The interaction between tumors and the cells of 
the immune system are also influenced by miRNAs [230]. There is now substantial 
evidence in a variety of cancer cell types including glioma, showing that microRNAs can 
impact expression of PD-L1 by either targeting it directly or targeting upstream effectors 
in its regulation [231]. This may be a potential mechanism by which the KD impacts 
expression of PD-L1.  
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Support for the hypothesis that the KD may impact expression of miRNAs comes 
from the study demonstrating that β-hydroxybutyrate (BHB), the major ketone elevated 
in the blood as a result of the ketogenic diet can also inhibit histone deacetylases 
(HDACs). HDACs are critical regulators of gene expression that enzymatically remove 
the acetyl group from histones, thus facilitating transcriptional repression. HDAC 
inhibitors are actively being tested for their ability to reverse the abnormal gene 
expression patterns inherent to the cancer epigenome which includes releasing 
transcriptional repression of anti-tumor microRNAs in a variety of cancers [13, 14].  A 
number of in vitro and in vivo studies have demonstrated the ability of chromatin‐
modifying drugs such as HDAC inhibitors to alter miRNA expression in cancer and has 
been reviewed thoroughly by Ali et al. [232]. The HDAC-inhibiting properties of BHB was 
first demonstrated in normal untransformed cells by Shimazu et al [53] but has only 
recently been demonstrated in the context of glioma cells which was demonstrated in 
Chapter 3. Given the evidence that the KD may work in part by epigenetic mechanisms, 
it was postulated that the KD may alter the expression of miRNAs that target expression 
of PD-L1. 
In this study we collaborated with Dr. Nelofer Syed at the Imperial College of 
London who performed RNA-sequencing on tumor tissue from animals maintained on 
the KD to assess the changes in miRNA expression. This data shows that the KD does 
in fact alter the expression of several microRNAs in glioma bearing-mice. miRNA target 
prediction software was then used to identify miRNAs that target the immune inhibitory 
checkpoint ligand PD-L1. Using these predictions as well as published studies from the 
literature we’ve identified multiple candidate miRNAs that may help explain the changes 
to PD-L1 expression described in Chapter 2 of this document and inform future studies. 
While the scope of this study is limited to PD-L1, this data offers a potential mechanism 
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that may be useful in describing the KDs impact on additional hallmarks of cancer with 
goal of better understanding the pluripotent nature of this approach.  
 
RESULTS 
 
The KD increases blood BHB, reduces blood glucose and slows tumor growth in vivo 
  
Tumor-bearing mice maintained on the ketogenic diet (KD) had significantly 
elevated blood BHB levels and reduced circulating blood glucose (Figure 21 A and B). 
Animals maintained on the KD also showed slower tumor growth rates as measured by 
bioluminescent imaging (Figure 21C). These results are consistent with work previously 
published in our laboratory [61, 62, 80, 127] as well as unpublished data.  
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Figure 21: The KD increases blood BHB, decreases blood glucose, and slows 
tumor growth in vivo. Blood ketone and glucose measurements show (A) higher BHB 
and (B) lower glucose in KD treated animals (C) bioluminescent tumor signals plotted as 
in vivo photon count versus days post-implantation. (N = 5; *p < 0.05; **p < 0.01; ***p < 
0.001). 
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KD increases significantly alters expression of several microRNAs  
 
RNAseq analysis was performed by our collaborator Dr. Nelofer Syed from the 
Imperial College of London on tumor tissue from animals treated with the KD versus 
those maintained on a standard rodent diet. These results demonstrate that the KD 
significantly increases expression of several miRNAs (Figure 22), many of which have 
demonstrated tumor suppressor properties in glioma [233]. Only statistically significant 
changes in expression were included in this graph.  
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Figure 22: The KD significantly alters the expression of multiple miRNAs. RNA-
sequencing analysis was performed on tumors from animals maintained on the KD and 
compared with those maintained on a standard rodent diet. Data is represented as a fold 
change in expression from standard diet fed controls (N=5).  
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The KD increases expression of miRNAs predicted to target PD-L1  
 
It was demonstrated in Chapter 2 that tumors from animals maintained on the KD 
showed reduced expression of the immune inhibitory ligand PD-L1. In an attempt to 
connect the results of that study to the miRNA changes found in the current study,  
miRanda target prediction software was used to generate a list of miRNAs predicted to 
target PD-L1. Out of the 147 miRNAs predicted to target PD-L1, 18 were also found to 
be upregulated in the tumors from animals maintained on the KD (Figure 23). Single 
miRNAs often bind and regulate multiple target genes. The study in Chapter 2 also 
demonstrated that the KD reduced CD86 expression which is another immune inhibitory 
checkpoint ligand. To determine if any of the 18 candidates also target CD86, miRNAs 
predicted to bind CD86 were compared those predicted to target PD-L1. The list was 
narrowed to 8 miRNAs significantly upregulated by the KD that are predicted to target 
both PD-L1 and CD86 (Figure 24).  
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Figure 23: The KD increases the expression of multiple miRNAs predicted to 
target PD-L1. miRanda target prediction software was used to identify miRNAs 
predicted to target PD-L1. These predictions were then compared to the list of miRNAs 
significantly upregulated in tumors from animals maintained on the KD.   
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Figure 24: The KD increases expression of miRNAs predicted to target both PD-L1 
and CD86. miRanda target prediction software was used to identify miRNAs predicted to 
target both immune inhibitory checkpoint ligands PD-L1 and CD86. These predictions 
were then compared to the list of miRNAs significantly upregulated in tumors from 
animals maintained on the KD.  
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DISCUSSION 
 
Advances in our understanding of the molecular biology of GBM have revealed 
that non-coding RNAs such as miRNAs are often dysregulated in GBM and many other 
cancers. This knowledge has led to the increased interest in leveraging miRNAs for 
cancer therapy and biomarker development [234]. In the present study, we found that 
the KD significantly alters the expression of several miRNAs in a mouse model of 
malignant glioma, many of which have been implicated in multiple hallmarks of cancer. 
miRNA target prediction software was used to determine which of these miRNAs may 
target PD-L1 expression and 18 candidates were identified. Some of these candidates 
have published interactions with PD-L1 and the immune system. For example miR-34a 
has been shown to directly target PD-L1 expression in glioma cells [235] and non-small 
cell lung cancer (NSCLC) cells [236, 237]. Others on the list such as the let-7 family of 
miRNAs have demonstrated tumor suppressor functions in several cancers including 
GBM [238] but no published interaction with PD-L1. Finally there are candidates on the 
list that have yet to be explored in the context of cancer and may be represent novel 
avenues for future studies.  
The most highly upregulated miRNA in tumors from animals maintained on the 
KD was miR-138. In multiple cancers including GBM, miR-138 has been shown to be 
downregulated and acts as a tumor suppressor [239-244]. Qiu et al showed that 
increased expression of miR-138 is associated with longer overall and progression-free 
survival in GBM patients [241]. While miR-138 targets many different genes involved in 
various hallmarks of cancer, there is also evidence showing it directly impacts immune 
inhibitory checkpoint pathways. For example a recent study demonstrated that miR-138 
directly targets PD-L1 in colorectal cancer cells [245]. The in vivo data from Chapter 2 
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showed significantly reduced expression of PD-L1 the tumors from animals maintained 
on the KD. Further, our collaborator Dr. Nelofer Syed has demonstrated that BHB 
treatment in vitro leads to significant upregulation of miR-138 in a human glioma cell line 
(unpublished data). Taken together this data suggests that the KD, due in part to BHB, 
may alter PD-L1 expression in glioma cells by upregulating miR-138.    
Mounting evidence demonstrates that tumors can influence with their 
microenvironment by secreting miRNAs [246]. Tumor immunity can be modulated by 
miRNAs and other non-coding RNAs that are transferred between tumor cells and 
immune cells in tumor microenvironments via exosomes or other microvesicles [230]. 
This suggests that the KD’s impact on miRNA expression in tumors may impact also 
impact T cells and other cells in the glioma microenvironment. Wei et al showed that 
intravenous administration of miR-138 in GL261-implanted mice slowed tumor growth 
and demonstrated significant downregulation of CTLA-4, PD-1, and FoxP3 on T cells in 
the tumor microenvironment [247]. Another study using the GL261 mouse glioma model 
demonstrated that miR-124, which is also commonly downregulated in GBM, slowed 
tumor growth and led to the increased production of IL-2, IFN-γ and TNF in tumor-
infiltrating lymphocytes indicating increased activation and effector function [248]. 
Interestingly both miR-138 and miR-124 were significantly upregulated in the tumors 
from animals maintained on the KD (Figure 14) our results from the study described in 
Chapter 2 describing the impact of the KD on T cells parallel the results of these two 
studies. It could therefore be postulated that the KD may lead to the increase in 
expression of miRNAs such as miR-138 or miR-124 in tumor cells which are then 
secreted into the microenvironment and impact immune function. Further studies 
exploring the ability of the KD to impact the microenvironment via secreted miRNAs are 
warranted.  
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miRNAs often have several target mRNAs and as literature and prediction 
software shows, multiple miRNAs can target the same mRNA impacting multiple aspects 
of tumor biology [249]. This lends to the complex nature of miRNA regulation of gene 
expression but it may also help us better understand the pluripotent nature of the KD.  
While the focus of this chapter is specifically on PD-L1 and immune modulation, the 
miRNAs altered by the KD target several different hallmarks of cancer (Table 2) [249-
254]. In addition, some of these miRNAs such as miR-138 and miR-34a (described 
above), target not only PD-L1 but other genes that have we’ve explored in the context of 
the KD. For example, miR-138 was shown to directly target a key effector in the 
response to hypoxia, hypoxia-inducible factor 1 α (HIF-1α) [240]. We previously 
demonstrated in a mouse model of malignant glioma that tumors from animals 
maintained on the KD have significantly reduced expression of HIF-1α [62]. Another 
example is miR-34a which targets PD-L1 as well as the key effector in DNA damage 
repair, RAD51 [255]. RAD51 is crucial for homologous recombination repair of double-
stranded DNA breaks and is overexpressed in several human cancers [180, 181]. The 
increased expression of RAD51 in cancer leads to resistance to double-stranded break 
inducing anti-cancer therapies [182-184]. We have demonstrated a reduction in RAD51 
protein expression in a variety of malignant glioma cells following treatment with BHB in 
vitro and in tumor tissue from animals maintained on a KD (Chapter 3). While miR-138 
and miR-34a offer two specific examples of crossover pathways, several additional 
miRNAs on this list can potentially be connected to previous studies.   
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Table 2: miRNAs upregulated by the KD target multiple hallmarks of cancer. 
miRNAs upregulated in tumors from animals maintained on the KD were compared to 
literature validating the role of specific miRNAs targeting various hallmarks of tumor 
growth and progression [249-254]. Symbols adapted from Hanahan and Weinberg et al. 
[7]. 
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The current study is far from validation of the roles specific miRNAs play in the 
anti-tumor effects of the KD. It does however provide a framework for future studies and 
may help us better explain our previous results. In addition to the several specific 
changes elicited by the KD discussed throughout this document, studies done in our 
laboratory using a mouse model of malignant glioma demonstrated that the KD exerts a 
global effect on the aberrant genetic landscape found in tumors [50]. Gene expression 
was compared in tumor tissue and tissue from the contralateral non-tumor containing 
side of the brain using cDNA array technology. This work showed that overall gene 
expression in tumor from animals fed the KD was shifted more towards the gene 
expression found in non-tumor containing tissue from animals fed either the KD or 
standard diet [61]. It is possible that the KD may alter global gene expression by altering 
the expression of several miRNAs. To our knowledge the current study provides the first 
evidence suggesting this, which moves us closer to understanding more completely the 
mechanisms underlying the KDs anti-tumor effects. 
 
METHODS 
 
Mice and tumor implantation 
  
GL261-Luc2 cells were harvested and implanted into mice as previously described in the 
methods section of Chapter 2 in this dissertation document and previous publications 
[62, 80, 127, 158]. 
 
Treatment and Animal Monitoring 
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Following implantation surgery, animals were fed standard rodent chow for 3 
days. Animals were then randomized to remain on standard diet (SD) or changed to a 
KD (KetoCal®; Nutricia North America, Gaithersburg, MD). The KD was obtained directly 
from the manufacturer and is a nutritionally complete diet providing a 4:1 ratio of fats to 
carbohydrates plus protein (72% fat, 15% protein, and 3% carbohydrate). The KD was 
prepared by mixing KetoCal® with water (2:1) and fed to the animals each day (ad 
libitum). Bioluminescence was analyzed to quantify tumor burden as described [80] 
Serum β-hydroxybutyrate (BHB) and glucose levels were measured using a Precision 
Xtra® blood monitoring system (Abbott Laboratories, Abbott Park, IL). 
 
Tissue Harvesting  
 
On Day 25 post-implantation, animals were euthanized and tumor tissue was 
snap frozen in liquid nitrogen.  
 
RNA isolation and miRNA Sequencing 
 
Flash frozen tumor samples were shipped to the laboratory of Dr. Nelofer Syed at 
the Imperial College in London. RNA was isolated and RNA-sequencing was performed.  
 
miRNA Prediction Analysis 
 
miRanda target prediction software was used to identify mouse and human 
miRNAs targeting mouse PD-L1 and CD86 [256-259]. These predictions were validated 
using TargetScan [260] and RNA22 [261] miRNA-target prediction programs.  
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CHAPTER 6 
DISCUSSION 
 
Glioblastoma multiforme (GBM) is the most aggressive primary cancer of the 
brain. Despite surgery followed by radiation and chemotherapy, these patients have a 
median survival time of ~15 months with a less than 6% five-year survival rate [262]. 
Complete surgical resection is precluded by the highly infiltrative nature of malignant 
brain tumors and the critical functions of the brain. Further, currently available therapies 
can kill most, but not all of the cells that remain after surgery, thus providing a seed for 
the formation of a recurrent tumor, typically within 2 years of their original diagnosis and 
in the same general area as the primary tumor. These tumors are often resistant to 
additional therapy with the same chemotherapy agents, and the use of additional 
radiation increases the risk of damage to adjacent normal tissue. In addition, once a 
tumor recurs following chemotherapy with temozolomide, there are few additional 
chemotherapeutic agents with demonstrated efficacy for the treatment of brain tumors. 
Advances in survival and quality of life rely on new therapeutic strategies, especially 
those that can enhance the efficacy of current treatment options. Despite decades of 
preclinical research and clinical trials the dismal prognosis for these patients remains 
largely unchanged. Novel, innovative therapeutic approaches are needed to improve 
patient outcomes. 
Evasion of the anti-tumor immune response has emerged as a crucial enabling 
characteristic of GBM. In particular, the ability of GBM to take advantage of immune 
inhibitor checkpoint pathways such as PD-1/PD-L1 is actively being explored as a 
therapeutic approach. For example, there have been a number of clinical trials initiated 
to determine the effectiveness of PD-1 checkpoint blockade in GBM [125]. While this 
  97 
approach has yet to be tested thoroughly in clinical trials, the PD-1 inhibitor nivolumab 
was recently proven ineffective as a monotherapy in recurrent GBM patients. Treatment 
with nivolumab alone failed to improve overall survival in recurrent GBM patients when 
compared to standard of care which is bevacizumab in a phase 3 trial (NCT02017717; 
KEYNOTE 028; ClinicalTrials.gov). This may reflect the mounting preclinical evidence 
suggesting that combining PD-1 blockade with additional checkpoint blockade or other 
immunotherapeutic strategies is more effective than monotherapy [141, 142, 263].   
 In Chapter 2 we investigated the impact of the KD on the glioma-reactive immune 
response in vivo. We demonstrate that mice fed the KD had increased tumor-reactive 
innate and adaptive immune responses, including increased cytokine production and 
cytolysis via tumor-reactive CD8+ T cells. Additionally, we saw that mice maintained on 
the KD had increased CD4+ infiltration, while T regulatory cell numbers stayed 
consistent. Lastly, mice fed the KD showed a significant reduction in expression of the 
immune inhibitory receptor PD-1 on T cells as well as decreased expression of the 
corresponding inhibitory ligand PD-L1 on glioma cells. These results suggest that the KD 
may work in part as an immune adjuvant, boosting tumor-reactive immune responses in 
the microenvironment by alleviating immune suppression. This evidence suggests that 
the KD increases tumor-reactive immune responses, and may have implications in 
combinational treatment approaches. 
To our knowledge this is the first published study to explore the KD in the context 
of anti-tumor immunity and demonstrate non-pharmalogical disruption of immune 
inhibitory checkpoint pathways; however, whether or not this results in better response 
to immune checkpoint blockade therapy has yet to be determined and warrants future 
studies. Although showing some preclinical efficacy, single agent checkpoint blockade 
therapy may be limited by redundant and compensatory mechanisms. For example, 
  98 
Huang et al demonstrated compensatory upregulation of PD-1 and CTLA-4 expression 
when using single-agent checkpoint blockade in metastatic ovarian cancer [264]. 
Preclinical evidence shows that combinatorial checkpoint blockade for glioma is more 
effective that any single immune checkpoint inhibitor alone [141, 142]. While the main 
focus of this proposal is the PD-1 checkpoint we have also demonstrated that the KD 
reduces expression of the cytotoxic T lymphocyte antigen-4 (CTLA-4) receptor on T cells 
and its corresponding ligand CD86 on glioma cells (Chapter 2) which is an additional 
immune inhibitory checkpoint mechanism and the focus of therapeutic development 
[133]. This suggests that the KD may potentially enhance the efficacy of immune 
checkpoint blockade strategies by reducing the expression of multiple inhibitory 
receptors/ligands and impairing compensatory upregulation. Further studies examining 
the impact of KD on these mechanisms are needed.  
While this dissertation document focuses mainly on the PD-1/PD-L1 pathway, 
there are additional promising immunotherapeutic strategies that may worth exploring in 
combination with KD. As mentioned above, therapeutics targeting CTLA-4 have shown 
promise alone and in combination with PD-1 and PD-L1 inhibitors and may be more 
effective when given in combination with KD. Another target in development is 
indoleamine 2,3 dioxygenase 1 (IDO1), which has emerged as another important 
immunosuppressive mechanism in gliomas and has led to the development of IDO1 
inhibitors, may be regulated by similar pathways driving PD-L1 expression [265]. IDO1 
inhibitors have shown promise in preclinical studies especially in combination with 
immune inhibitory checkpoint inhibitors [141] and temozolomide [266]. Further studies 
exploring KD in combination with IDO1 inhibition and additional novel 
immunotherapeutic strategies including may be warranted.  
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While the KD may impact tumor-mediated immune suppression, this is not the 
only anti-tumor mechanism to consider. Our laboratory previously published a study 
demonstrating that the KD greatly enhances survival in a mouse model of malignant 
glioma when combined with radiation [80]. The in vitro studies described in Chapter 3 
suggest that BHB may play a large role in KD-mediated radiosensitization by inhibiting 
HDACs and impairing radiation-induced DNA damage repair capabilities in glioma cells. 
As radiation-induced tumor cell killing is known to be immunogenic, it is possible that the 
KD also indirectly enhances the anti-tumor immune response by augmenting the effect 
of radiation. The interactions between radiation and the immune system have been 
investigated, with several studies describing the synergistic effects on local and distant 
tumor control when radiation therapy is combined with immunotherapy [167, 168]. 
Interestingly, several recent studies now have suggested that PD-L1 expression may be 
linked to radiation response in cancer [267-272], providing another interesting avenue 
linking the radiation and immune enhancing properties of the KD. Taken together, the 
data described in each of the studies in this dissertation suggest that the KD may exert 
multiple anti-tumor pressures simultaneously, thus making it an attractive adjuvant to 
both standard of care and immunotherapies. 
In Chapter 4 we investigated the impact of BHB on PD-L1 expression on glioma 
cells and PD-1 expression on T cells. We show that BHB treatment of glioma cells in 
vitro leads to a reduction in PD-L1 expression. However, BHB failed to change 
expression of the immune inhibitory receptors including PD-1 on T cells in vitro 
suggesting an alternative mechanism may explain the in vivo results from Chapter 2. 
These results may also warrant further in vitro studies to combine reduced glucose 
conditions with BHB treatment to more accurately recapitulate the conditions of a full KD. 
To our knowledge this is the first study examining the impact of BHB on the PD-1/PD-L1 
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pathway and represents a novel mechanism underlying the KD and its ability to alter the 
way tumor cells interact with the immune system. This data lends to the growing body of 
evidence from our laboratory and others demonstrating that BHB acts as more than a 
simple replacement energy substrate and may drive many of the anti-tumor effects of the 
KD [79]. This work supports the growing idea that ketones may be effective in 
supplementing the rigors of a full ketogenic diet or perhaps replacing it.  
In Chapter 5, we investigated the impact of the KD on expression of miRNAs in 
collaboration with the Syed Laboratory and found that the tumors from animals 
maintained on the KD have significantly increased expression of several different 
miRNAs. Screening this list we find that several of these miRNAs are predicted to target 
PD-L1, some of which have already been experimentally validated in previously 
published studies. This data suggest one potential mechanism by which the KD may act 
on immune inhibitory checkpoint pathways. This was supported by work done in the 
laboratory of our collaborator Dr. Nelofer Syed showing that treatment of glioma cells 
with BHB in vitro upregulates expression of miR-138 (unpublished data), which is a 
tumor-suppressor miRNA and targets PD-L1 in cancer cells [245] as well as PD-1 and 
other immune checkpoint pathways in T cells [247]. Future studies connecting the 
upregulation of miR-138 and other miRNAs by KD-mediated changes in PD-1 or PD-L1 
expression are warranted. However, as discussed in Chapter 4 there are multiple 
pathways beyond tumor-immune interaction that are impacted by the miRNAs 
upregulated by the KD which may reveal a broader mechanism by which the KD impacts 
multiple hallmarks of cancer.    
As interest in using the KD for brain tumor patients continues to grow rapidly, 
greater understanding of the mechanisms underlying this approach are needed, 
particularly as they pertain to its potential to augment other therapies. The work in this 
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dissertation is the first to describe the impact of the KD on the anti-glioma immune 
response and thus provides a foundation for better understanding how it may work in 
combination with immunotherapeutic strategies. Taken together with other studies 
conducted in our laboratory, this work contributes significantly to the overall goal of 
developing the ketogenic diet as an effective adjuvant strategy for malignant glioma.
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